Document/ExhibitDescriptionPagesSize 1: 10-Q Quarterly Report HTML 1.97M
2: EX-10.2 Material Contract HTML 219K
3: EX-10.3 Material Contract HTML 194K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 35K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 35K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 30K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 30K
85: R1 Document And Entity Information Document HTML 81K
39: R2 Consolidated Balance Sheets HTML 161K
25: R3 Consolidated Balance Sheets (Parenthetical) HTML 52K
55: R4 Consolidated Statements Of Income HTML 104K
84: R5 Consolidated Statements of Comprehensive Income HTML 58K
38: R6 Consolidated Statements Of Cash Flows HTML 159K
23: R7 Consolidated Statements Of Shareholders' Equity HTML 115K
52: R8 Organization HTML 34K
88: R9 Basis Of Presentation and Significant Accounting HTML 70K
Policies
30: R10 Business Acquisitions HTML 33K
43: R11 Investments HTML 260K
92: R12 Derivative Financial Instruments Derivative HTML 32K
Financial Instruments
61: R13 Fair Value HTML 416K
31: R14 Income Taxes HTML 33K
44: R15 Retirement Benefits HTML 82K
93: R16 Medical Claims Payable HTML 155K
62: R17 Debt HTML 54K
32: R18 Commitments And Contingencies HTML 58K
42: R19 Capital Stock HTML 118K
76: R20 Accumulated Other Comprehensive Income HTML 108K
67: R21 Earnings Per Share HTML 46K
13: R22 Segment Information HTML 177K
45: R23 Leases HTML 62K
78: R24 Basis of Presentation and Significant Accounting HTML 85K
Policies (Policies)
68: R25 Investments (Tables) HTML 266K
14: R26 Fair Value (Tables) HTML 402K
46: R27 Retirement Benefits (Tables) HTML 81K
75: R28 Medical Claims Payable (Tables) HTML 161K
69: R29 Debt (Tables) HTML 35K
65: R30 Capital Stock (Tables) HTML 126K
95: R31 Accumulated Other Comprehensive Income (Tables) HTML 110K
41: R32 Earnings Per Share (Tables) HTML 43K
29: R33 Segment Information (Tables) HTML 182K
64: R34 Leases (Tables) HTML 65K
94: R35 Organization (Details) HTML 33K
40: R36 Basis of Presentation and Signficant Accounting HTML 51K
Policies Basis of Presentation and Significant
Acconting Policies (Details)
28: R37 Business Acquisitions Business Acquisition (Assets HTML 42K
Liabilities Acquired) (Details)
63: R38 Investments (Current And Long-Term Fixed Maturity HTML 77K
Securities, Available-For-Sale) (Details)
96: R39 Investments (Aggregate Fair Value And Gross HTML 73K
Unrealized Loss Of Fixed Maturity Securities In An
Unrealized Loss Position) (Details)
72: R40 Investments (Amortized Cost And Fair Value Of HTML 64K
Fixed Maturity Securities, By Contractual
Maturity) (Details)
80: R41 Investments (Proceeds and Realized Gains Losses HTML 35K
From Fixed Maturity Securities) (Details)
51: R42 Investments (Current and Long-term Equity HTML 37K
Securities) (Details)
19: R43 Investments (Gains and Losses Recognized on Equity HTML 36K
Securities) (Details)
71: R44 Investments (Securities Lending Programs) HTML 40K
(Details)
79: R45 Investments (Narrative) (Details) HTML 34K
50: R46 Derivative Financial Instruments (Financial HTML 35K
Statement Narrative) (Details)
18: R47 Fair Value (Fair Value Measurements By Level For HTML 152K
Assets Measured At Fair Value On A Recurring
Basis) (Details)
70: R48 Fair Value (Reconciliation Of The Beginning And HTML 79K
Ending Balances Of Assets Measured At Fair Value
On A Recurring Basis Using Level III Inputs)
(Details)
81: R49 Fair Value (Carrying And Estimated Fair Values by HTML 59K
Level Of Financial Instruments Not Recorded At
Fair Value On Consolidated Balance Sheet)
(Details)
87: R50 Income Taxes (Narrative) (Details) HTML 37K
53: R51 Retirement Benefits (Components Of Net Periodic HTML 56K
(Benefit Credit) Benefit Cost) (Details)
26: R52 Retirement Benefits (Narrative) (Details) HTML 30K
36: R53 Medical Claims Payable (Reconciliation Of The HTML 83K
Beginning And Ending Balances For Medical Claims
Payable By Segment) (Details)
89: R54 Medical Claims Payable (Reconciliation Of Net HTML 44K
Incurred Medical Claims To Benefit Expense)
(Details)
54: R55 Medical Claims Payable Medical Claims Payable HTML 50K
(Reconciliation of the Claims Development to the
Claims Liability) (Details)
27: R56 Medical Claims Payable (Narrative) (Details) HTML 43K
37: R57 Debt (Convertible Debenture Details) (Details) HTML 47K
86: R58 Debt (Narrative) (Details) HTML 132K
56: R59 Commitments And Contingencies (Details) HTML 48K
15: R60 Capital Stock (Summary of Cash Dividend Activity) HTML 43K
(Details)
48: R61 Capital Stock (Summary of Share Repurchases) HTML 47K
(Details)
82: R62 Capital Stock (Summary of Stock Option Activity) HTML 68K
(Details)
73: R63 Capital Stock (Nonvested Restricted Stock Activity HTML 54K
Including Restricted Stock Units) (Details)
16: R64 Capital Stock (Fair Values of Options Granted HTML 39K
During The Period Estimated Using Weighted-Average
Assumptions) (Details)
49: R65 Capital Stock (Schedule Of Weighted-Average Fair HTML 33K
Values Determined For The Periods) (Details)
83: R66 Capital Stock (Narrative) (Details) HTML 50K
74: R67 Accumulated Other Comprehensive Loss HTML 89K
(Reconciliation Of The Components Of Accumulated
Other Comprehensive Income) (Details)
17: R68 Accumulated Other Comprehensive Income (Other HTML 55K
Comprehensive Income (Loss) Reclassification
Adjustments) (Details)
47: R69 Accumulated Other Comprehensive Income (Loss) HTML 50K
Accumulated Other Comprehensive Income
Reclassification Adjustments (Details)
34: R70 Earnings Per Share (Denominator For Basic And HTML 36K
Diluted Earnings Per Share) (Details)
22: R71 Earnings Per Share (Narrative) (Details) HTML 35K
58: R72 Segment Information (Financial Data By Reportable HTML 57K
Segment) (Details)
91: R73 Segment Information Segment Information (Major HTML 52K
Product Revenues for Each Reportable Segment)
(Details)
33: R74 Segment Information (Reconciliation Of Reportable HTML 41K
Segments Operating Revenues To Total Revenues
Reported In The Consolidated Statements Of Income)
(Details)
21: R75 Segment Information (Reconciliation Of Reportable HTML 50K
Segments Operating Gain To Income Before Income
Tax Expense Included In The Consolidated
Statements Of Income) (Details)
57: R76 Segment Information Segment Information HTML 29K
(Narrative) (Details)
90: R77 Leases (Lease and Other Information) (Details) HTML 57K
35: R78 Leases (Reconciliation of Future Lease Payments to HTML 47K
Total Lease Liabilities) (Details)
20: R79 Leases (Narrative) (Details) HTML 41K
59: XML IDEA XML File -- Filing Summary XML 182K
60: XML XBRL Instance -- antm-2019930x10q_htm XML 4.66M
66: EXCEL IDEA Workbook of Financial Reports XLSX 123K
9: EX-101.CAL XBRL Calculations -- antm-20190930_cal XML 294K
10: EX-101.DEF XBRL Definitions -- antm-20190930_def XML 1.14M
11: EX-101.LAB XBRL Labels -- antm-20190930_lab XML 2.57M
12: EX-101.PRE XBRL Presentations -- antm-20190930_pre XML 1.59M
8: EX-101.SCH XBRL Schema -- antm-20190930 XSD 251K
24: JSON XBRL Instance as JSON Data -- MetaLinks 511± 815K
77: ZIP XBRL Zipped Folder -- 0001156039-19-000016-xbrl Zip 492K
(Exact name of registrant as specified in its charter)
iIndiana
i35-2145715
(State
or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
i220 Virginia Avenue
iIndianapolis,
iIndianai46204
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (i800) i331-1476
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbol(s)
Name of each exchange on which registered
iCommon
Stock, $0.01 par value
iANTM
iNew York Stock Exchange
Indicate by check mark whether the
registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. iYes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive
Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). iYes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:
iLarge accelerated filer
☒
Accelerated filer
☐
Non-accelerated
filer
☐
Smaller reporting company
i☐
Emerging growth company
i☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes i☐ No ☒
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
1.
i
Organization
References to the terms “we,”“our,”“us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia, unless the context otherwise requires.
We
are one of the largest health benefits companies in the United States in terms of medical membership, serving approximately i41medical members through our affiliated health plans as of September 30, 2019. We offer a broad spectrum of network-based managed care plans to Large Group, Small Group, Individual, Medicaid and Medicare markets. Our managed care plans include: Preferred Provider Organizations, or PPOs; Health Maintenance Organizations,
or HMOs; Point-of-Service plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans, and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance products and services such as dental, vision, life and disability insurance benefits, radiology benefit management and analytics-driven personal health care. We also provide services to the federal government in connection with our Federal Health Products & Services business.
We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. We
serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding i30counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do
business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees. Through our subsidiaries, we serve customers in numerous states across the country as America’s 1st Choice, Amerigroup, Aspire Health, CareMore, Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply Healthcare, and/or Unicare. Also, beginning in the second quarter of 2019, we provide pharmacy benefits management services through our IngenioRx subsidiary. We are licensed to conduct insurance operations in all i50
states and the District of Columbia through our subsidiaries.
2.
i
Basis of Presentation and Significant Accounting Policies
i
Basis
of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our 2018 Annual Report on Form 10-K, unless the information contained in those disclosures materially changed or is required by GAAP. Certain prior year amounts have been reclassified to conform to the current year presentation or adjusted to conform to the current year rounding convention of reporting financial data in whole millions of dollars, except as otherwise noted. For additional information on prior year reclassifications, see Note 15, “Segment Information.” In the opinion
of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and nine months ended September 30, 2019 and 2018 have been recorded. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2019, or any other period. These unaudited consolidated financial statements
should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2018 included in our 2018 Annual Report on Form 10-K.
i
Certain of our subsidiaries operate outside of the United States and have functional currencies
other than the U.S. dollar, or USD. We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the
-8-
period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
i
Cash
and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits and have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $i242 and $i222
at September 30, 2019 and December 31, 2018, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
/i
Leases:We lease office space and certain computer and related equipment under noncancelable operating leases. We determine
whether an arrangement is or contains a lease at its inception. We recognize lease liabilities based on the present value of the minimum lease payments not yet paid by using the lease term, any amounts probable of being owed under any residual value guarantees and discount rate determined at lease commencement. As our leases do not generally provide an implicit rate, we use our incremental secured borrowing rate commensurate with the underlying lease terms to determine the present value of our lease payments. Our leases may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. We recognize the operating right-of-use, or ROU, assets at an amount equal to the lease liability adjusted for prepaid or accrued rent, the remaining balance of any lease incentives and unamortized initial direct costs.
The operating lease liabilities are reported in other current liabilities and
other noncurrent liabilities and the related ROU assets are reported in other noncurrent assets on our consolidated balance sheet as of September 30, 2019. Lease expense for our operating leases is calculated on a straight-line basis over the lease term and is reported in selling, general and administrative expense on our consolidated statements of income. For our office space leases, we account for the lease and non-lease components (such as common area maintenance) as a single lease component. We also do not recognize a lease liability or ROU asset for our office space leases whose lease terms, at commencement, are twelve months or less and that do not include a purchase option or option to extend that we are reasonably certain to exercise.
i
Revenue
Recognition: Premiums for fully-insured contracts are recognized as revenue over the period insurance coverage is provided, and, if applicable, net of amounts recognized for the minimum medical loss ratio rebates or contractual or government-mandated premium stabilization programs. Administrative fees and other revenues include revenue from certain group contracts that provide for the group to be at risk for all, or with supplemental insurance arrangements, a portion of their claims experience. We charge these self-funded groups an administrative fee, which is based on the number of members in a group or the group’s claim experience. Under our self-funded arrangements, revenue is recognized as administrative services are performed, and benefit payments under these
programs are excluded from benefit expense. Beginning in the second quarter of 2019, administrative fees and other revenues also include unaffiliated revenue from services performed by IngenioRx. For additional information about our revenues, see Note 2, “Basis of Presentation and Significant Accounting Policies” and Note 19, “Segment Information,” to our audited consolidated financial statements as of and for the year ended December 31, 2018 included in our 2018 Annual Report on Form 10-K. In addition, see Note 15, “Segment Information,” herein for the disaggregation of revenues by segments and products.
For our non-fully-insured contracts, we had no material
contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at September 30, 2019. For the three and nine months ended September 30, 2019, revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related
to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
i
Recently Adopted Accounting Guidance: In March 2019, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2019-01, Leases (Topic 842): Codification Improvements. In July
2018, the FASB issued Accounting Standards Update No. 2018-11, Leases (Topic 842): Targeted Improvements and Accounting Standards Update No. 2018-10, Codification Improvements to Topic 842, Leases. These updates provide additional clarification, an optional transition method, a practical expedient and implementation guidance on the previously issued Accounting Standards Update No. 2016-02, Leases (Topic 842). Collectively, these updates supersede the lease guidance in Accounting Standards Codification, or ASC, Topic 840 and require lessees to recognize for all leases, with the exception of short-term leases, a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis.
-9-
Concurrently,
lessees are required to recognize an ROU asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. We adopted this standard on January 1, 2019 by applying the optional transition method on the adoption date and did not adjust comparative periods. We also elected the package of practical expedients permitted, which, among other things, allowed us to carry forward the lease classification for our existing leases. In preparation for the adoption of this standard and to enable preparation of the required financial information, we implemented a new lease accounting software solution as well as new internal controls. The adoption of this standard impacted our 2019 opening consolidated balance sheet, as we recorded operating lease liabilities of $i728
and ROU assets of $i637, which equals the lease liabilities net of accrued rent, lease incentives and the carrying amount of ceased-use liabilities previously recorded on our consolidated balance sheet under the old guidance. We also recognized a cumulative-effect adjustment of $i26
to our opening retained earnings for deferred gains on our previous sale-leaseback transactions. The adoption of this standard did not have an impact on our consolidated statements of income or cash flows.
In August 2018, the FASB issued Accounting Standards Update No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, or ASU 2018-13. The amendments in ASU 2018-13 eliminate, add, and modify certain disclosure requirements for fair value measurements. The amendments are effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted for either the entirety of ASU 2018-13 or only the provisions that eliminate or modify disclosure requirements. We early adopted the provisions that eliminate and modify disclosure
requirements, on a retrospective basis, effective in our 2018 Annual Report on Form 10-K. We will adopt the new disclosure requirements, on a prospective basis, effective for our interim and annual reporting periods beginning after December 15, 2019.
In February 2018, the FASB issued Accounting Standards Update No. 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, or ASU 2018-02. On December 22, 2017, the federal government enacted a tax bill, H.R.1, An act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018, or the Tax Cuts and Jobs Act. The Tax Cuts and Jobs
Act contains significant changes to corporate taxation, including, but not limited to, reducing the U.S. federal corporate income tax rate from 35% to 21% and modifying or limiting many business deductions. Current FASB guidance requires adjustments of deferred taxes due to a change in the federal corporate income tax rate to be included in income from operations. As a result, the tax effects of items within accumulated other comprehensive loss did not reflect the appropriate tax rate. The amendments in ASU 2018-02 allowed a reclassification from accumulated other comprehensive loss to retained earnings for stranded tax effects resulting from the change in the federal corporate income tax rate. We adopted the amendments in ASU 2018-02 for our interim and annual reporting periods beginning on January 1, 2018 and reclassified $i91
of stranded tax effects from accumulated other comprehensive loss to retained earnings on our consolidated balance sheets. The adoption of ASU 2018-02 did not have any impact on our consolidated results of operations or cash flows.
In May 2017, the FASB issued Accounting Standards Update No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, or ASU 2017-09. This update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718. We adopted ASU 2017-09 on January 1, 2018. The guidance has been and will be applied prospectively to awards modified on or after the adoption date. The adoption of ASU 2017-09 did not have any impact on our consolidated financial position, results of operations or
cash flows.
In March 2017, the FASB issued Accounting Standards Update No. 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities, or ASU 2017-08. This update changes the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. Under the old guidance, the premium was generally amortized over the contractual life of the instrument. The amendments are to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We adopted ASU 2017-08 on January 1, 2019, and the adoption of this standard did not have a material impact on our beginning retained
earnings or on our consolidated financial position, results of operations or cash flows.
In March 2017, the FASB issued Accounting Standards Update No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, or ASU 2017-07. This amendment requires entities to disaggregate the service cost component from the other components of the
-10-
benefit cost and present the service cost component in the same income statement line item as other employee compensation costs arising from services rendered by the pertinent employees
during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. Certain of our defined benefit plans have previously been frozen, resulting in no annual service costs, and the remaining service costs for our non-frozen plan are not material. We adopted ASU 2017-07 on January 1, 2018, and it did not have a material impact on our consolidated results of operations, cash flows or financial position.
In December 2016, the FASB issued Accounting Standards Update No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. In May 2016, the FASB issued Accounting
Standards Update No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients. In April 2016, the FASB issued Accounting Standards Update No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. In March 2016, the FASB issued Accounting Standards Update No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). These updates provide additional clarification and implementation
guidance on the previously issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). Collectively, these updates require a company to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. These updates supersede almost all existing revenue recognition guidance under GAAP, with certain exceptions, including an exception for our premium revenues, which are recorded on the Premiums line item on our consolidated statements of income and will continue to be accounted for in accordance with the provisions of ASC Topic 944, Financial Services
- Insurance. Our administrative service and other contracts that are subject to these Accounting Standards Updates are recorded in the Administrative fees and other revenue line item on our consolidated statements of income and represent approximately i6% of our consolidated total operating revenue. We adopted these standards on January
1, 2018 using the modified retrospective approach. The adoption of these standards did not have a material impact on our beginning retained earnings, or on our consolidated results of operations, cash flows or financial position.
In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, or ASU 2016-18. This update amends ASC Topic 230, Statement of Cash Flows, to add and clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. The guidance requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. We adopted ASU 2016-18 on January 1, 2018 using a retrospective approach.
The adoption of ASU 2016-18 did not have a material impact on our consolidated statements of cash flows and did not impact our consolidated results of operations or financial position.
In August 2016, the FASB issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, or ASU 2016-15. This update addresses the presentation and classification on the statement of cash flows for eight specific items, with the objective of reducing existing diversity in practice in how certain cash receipts and cash payments are presented and classified. We adopted ASU 2016-15 on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact on our consolidated statements of cash flows, results of operations or financial position.
In
January 2016, the FASB issued Accounting Standards Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, or ASU 2016-01. The amendments in ASU 2016-01 change the accounting for non-consolidated equity investments that are not accounted for under the equity method of accounting by requiring changes in fair value to be recognized in income. Additionally, ASU 2016-01 simplifies the impairment assessment of equity investments without readily determinable fair values; requires entities to use the exit price when estimating the fair value of financial instruments; and modifies various presentation disclosure requirements for financial instruments. We adopted ASU 2016-01 on January 1, 2018 as a cumulative-effect adjustment and reclassified $i320
of unrealized gains on equity investments, net of tax, from accumulated other comprehensive loss to retained earnings on our consolidated balance sheets. Effective January 1, 2018, our results of operations include the changes in fair value of these financial instruments.
i
Recent Accounting Guidance Not Yet Adopted: In May 2019, the FASB issued Accounting Standards Update No. 2019-05, Financial Instruments - Credit Losses
(Topic 326): Targeted Transition Relief, or ASU 2019-05. In April 2019, the FASB issued Accounting Standards Update No. 2019-04, Codification Improvements to Topic 326, Financial Instruments -
-11-
Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments. In November 2018, the FASB issued Accounting Standards Update No. 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. These updates provide an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost and
provide additional clarification and implementation guidance on certain aspects of the previously issued Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, or ASU 2016-13, and have the same effective date and transition requirements as ASU 2016-13. ASU 2016-13 introduces a current expected credit loss model for measuring expected credit losses for certain types of financial instruments held at the reporting date based on historical experience, current conditions and reasonable supportable forecasts. ASU 2016-13 replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available-for-sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities and provides for additional disclosure requirements. ASU
2016-13 requires a cumulative-effect adjustment to the statement of financial position to the opening balance of retained earnings at the date of adoption and a prospective transition approach for debt securities for which an other-than-temporary impairment had been recognized before the adoption date. The effect of a prospective transition approach is to maintain the same amortized cost basis before and after the date of adoption. ASU 2016-13 is effective for us on January 1, 2020, with early adoption permitted. We are currently gathering data and evaluating the effects the adoption of ASU 2016-13 will have on our consolidated financial statements.
In August 2018, the FASB issued Accounting Standards Update No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in
a Cloud Computing Arrangement that is a Service Contract, or ASU 2018-15. The amendments in ASU 2018-15 require implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement, if those costs would be capitalized by the customer in a software licensing arrangement under the internal-use software guidance. The amendments also require an entity to disclose the nature of its hosting arrangements and adhere to certain presentation requirements in its balance sheet, income statement and statement of cash flows. ASU 2018-15 is effective for us on January 1, 2020, with early adoption permitted. The guidance can be applied either prospectively to all implementation costs incurred after the date of adoption or retrospectively. While we are continuing
to evaluate the effects the adoption of ASU 2018-15 will have on our consolidated financial position, results of operations and cash flows; we intend to apply the prospective method of adoption.
In August 2018, the FASB issued Accounting Standards Update No. 2018-14, Compensation—Retirement Benefits - Defined Benefit Plans—General (Subtopic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans, or ASU 2018-14. The amendments in ASU 2018-14 eliminate, add, and modify certain disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The amendments are effective for our annual reporting periods beginning after December 15, 2020, with early adoption permitted. The guidance is to be applied on a retrospective basis to all periods presented. We are
currently evaluating the effects the adoption of ASU 2018-14 will have on our disclosures.
In August 2018, the FASB issued Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, or ASU 2018-12. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The
amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments in ASU 2018-12 will be effective for our interim and annual reporting periods beginning after December 15, 2020. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect
adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments for market risk benefits are to be applied retrospectively. We are currently evaluating the effects the adoption of ASU 2018-12 will have on our consolidated financial position, results of operations, cash flows, and related disclosures.
-12-
In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, or ASU 2017-04. This update removes Step 2 of the goodwill impairment test under current guidance, which requires a hypothetical purchase price allocation.
The new guidance requires an impairment charge to be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value. Upon adoption, the guidance is to be applied prospectively. ASU 2017-04 is effective for us on January 1, 2020, with early adoption permitted. The adoption of ASU 2017-04 is not expected to have a material impact on our consolidated financial position, results of operations or cash flows.
There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2018 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.
3.
i
Business
Acquisitions
Pending Acquisition of Beacon
On June 6, 2019, we announced our entrance into an agreement to acquire Beacon Health Options, Inc., or Beacon, the largest independently held behavioral health organization in the country. Beacon serves approximately forty million individuals across all fifty states. This acquisition aligns with our strategy to diversify into health services and deliver both integrated solutions and care delivery models that personalize care for people with complex and chronic conditions. The acquisition is expected to close late in the fourth quarter of 2019 and is subject to standard closing conditions and customary approvals.
Acquisition of America’s 1st Choice
On
February 15, 2018, we completed our acquisition of Freedom Health, Inc., Optimum HealthCare, Inc., America’s 1st Choice of South Carolina, Inc. and related entities, or collectively, America’s 1st Choice, a Medicare Advantage organization that offers HMO products, including Chronic Special Needs Plans and Dual-Eligible Special Needs Plans under its Freedom Health and Optimum HealthCare brands in Florida and its America’s 1st Choice of South Carolina brand in South Carolina. Upon the conclusion of our one-year measurement period, the excess of the consideration transferred over the fair value of the net assets acquired resulted in goodwill of $i1,029,
of which $i333 was tax deductible. All of the goodwill was allocated to our Government Business segment. The results of operations of America’s 1st Choice are included in our consolidated financial statements within our Government Business segment for the periods following February
15, 2018.
4.
i
Investments
Fixed Maturity Securities
We
evaluate our available-for-sale fixed maturity securities for other-than-temporary declines based on qualitative and quantitative factors. There were no individually significant other-than-temporary impairment losses on investments during the three and nine months ended September 30, 2019 and 2018. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and additional material other-than-temporary impairment, or OTTI, losses on investments may be recorded in future periods.
-13-
i
A
summary of current and long-term fixed maturity securities, available-for-sale, at September 30, 2019 and December 31, 2018 is as follows:
For
fixed maturity securities in an unrealized loss position at September 30, 2019 and December 31, 2018, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position:
The
amortized cost and fair value of fixed maturity securities at September 30, 2019, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.
Amortized
Cost
Estimated
Fair
Value
Due in one year or less
$
i628
$
i628
Due
after one year through five years
i5,569
i5,701
Due
after five years through ten years
i5,504
i5,731
Due
after ten years
i4,065
i4,311
Mortgage-backed
securities
i4,001
i4,107
Total
fixed maturity securities
$
i19,767
$
i20,478
/
-15-
i
Proceeds
from sales, maturities, calls or redemptions of fixed maturity securities and the related gross realized gains and gross realized losses for the three and nine months ended September 30, 2019 and 2018 are as follows:
Three
Months Ended September 30
Nine Months Ended September 30
2019
2018
2019
2018
Proceeds
$
i2,048
$
i1,532
$
i5,502
$
i6,413
Gross
realized gains
i26
i12
i66
i73
Gross
realized losses
(i9
)
(i16
)
(i43
)
(i85
)
/
In
the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.
All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
The
gains and losses related to equity securities for the three and nine months ended September 30, 2019 and 2018 are as follows:
Three Months Ended September 30
Nine
Months Ended September 30
2019
2018
2019
2018
Net realized (losses) gains recognized on equity securities
$
(i16
)
$
i27
$
i75
$
(i33
)
Less:
Net realized gains recognized on equity securities sold during the period
(i6
)
(i11
)
(i55
)
(i208
)
Unrealized
(losses) gains recognized on equity securities still held at September 30
$
(i22
)
$
i16
$
i20
$
(i241
)
/
Securities
Lending Programs
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to $i465 and $i604
at September 30, 2019 and December 31, 2018, respectively. The value of the collateral represented i103% and i102%
of the market value of the securities on loan at September 30, 2019 and December 31, 2018, respectively. We recognize the collateral as an asset under the caption “Securities lending collateral” on our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Securities lending payable.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets.
-16-
i
The
remaining contractual maturity of our securities lending agreements at September 30, 2019 is as follows:
Overnight and Continuous
Securities lending transactions
United States Government securities
$
i132
Corporate
securities
i324
Equity securities
i9
Total
$
i465
/
The
market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the minimum collateral level is set at i102%
of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
5.
i
Derivative
Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions.
We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the London Interbank Offered Rate.
Prior to 2019, we entered
into a series of forward starting pay fixed interest rate swaps with the objective of reducing the variability of cash flows in the interest payments on anticipated future financings. The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $i277
and $i246 at September 30, 2019 and December 31, 2018, respectively.
For additional information relating to the fair value of our derivative assets and liabilities, see Note 6, “Fair Value,” of this Form 10-Q.
6.
i
Fair Value
Assets and
liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:
Level Input
Input Definition
Level I
Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at
the measurement date.
Level II
Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III
Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
-17-
The
following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in our consolidated balance sheets:
Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.
Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements
and disclosures. Level II securities primarily include United States Government securities, corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity
securities, primarily corporate debt securities, which are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.
Equity securities: Fair values of equity securities with quoted market prices are designated as Level I. For certain equity securities, quoted market prices for the identical security are not always available and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security’s current condition and future cash flow projections.
Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.
Other invested assets, current: Other invested assets, current include securities held in rabbi trusts that are classified as trading. These securities are designated Level I securities, as fair values are based on quoted market prices.
Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services,
which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures.
Derivatives: Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate observable market inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by counterparty.
-18-
i
A
summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at September 30, 2019 and December 31, 2018 is as follows:
Total
fixed maturity securities, available-for-sale
i2
i16,867
i310
i17,179
Equity
securities:
Exchange traded funds
i2
i—
i—
i2
Fixed
maturity mutual funds
i—
i557
i—
i557
Common
equity securities
i601
i53
i—
i654
Private
equity securities
i—
i—
i313
i313
Total
equity securities
i603
i610
i313
i1,526
Other
invested assets, current
i21
i—
i—
i21
Securities
lending collateral
i314
i290
i—
i604
Derivatives
i—
i16
i—
i16
Total
assets
$
i2,755
$
i17,783
$
i623
$
i21,161
Liabilities:
Derivatives
$
i—
$
(i17
)
$
i—
$
(i17
)
Total
liabilities
$
i—
$
(i17
)
$
i—
$
(i17
)
/
-19-
i
A
reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended September 30, 2019 and 2018 is as follows:
Change
in unrealized gains included in net income related to assets still held at September 30, 2018
$
i—
$
i—
$
i—
$
i9
$
i9
/
-20-
A
reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the nine months ended September 30, 2019 and 2018 is as follows:
Change
in unrealized gains included in net income related to assets still held at September 30, 2018
$
i—
$
i—
$
i—
$
i27
$
i27
There
were no individually material transfers into or out of Level III during the three and nine months ended September 30, 2019 or 2018.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions,” we completed our acquisition of America’s 1st Choice on February 15, 2018. The net assets acquired in our acquisition of America’s 1st Choice and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of America’s
1st Choice’s assets acquired and liabilities assumed were recorded at their carrying values as of the respective date of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisition of America’s 1st Choice were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisition of America’s 1st Choice described above, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the three and nine months ended September 30,
2019 or 2018.
-21-
Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. Potential taxes and other transaction costs are not considered in estimating fair values.
Our valuation policy is generally to obtain quoted prices for each security from third party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform a monthly analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the three and nine
months ended September 30, 2019 or 2018.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated balance sheets.
Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.
The
carrying amounts reported in our consolidated balance sheets for cash and cash equivalents, accrued investment income, premium receivables, self-funded receivables, other receivables, income taxes receivable/payable, unearned income, accounts payable and accrued expenses, security trades pending payable, securities lending payable and certain other current liabilities approximate fair value because of the short term nature of these items. These assets and liabilities are not listed in the table below.
The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our consolidated balance sheets:
Other invested assets, long-term: Other invested assets, long-term include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations,
as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.
Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt – commercial paper: The carrying amount for commercial paper approximates fair value, as the underlying
instruments have variable interest rates at market value.
Long-term debt – senior unsecured notes and surplus notes: The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt – convertible debentures: The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade.
-22-
i
A
summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at September 30, 2019 and December 31, 2018 is as follows:
During the three months ended September 30, 2019 and 2018, we recognized income tax expense of $i306
and $i282, respectively, which represent effective tax rates of i20.6% and i22.7%,
respectively. The increase in income tax expense was primarily due to the 2018 remeasurement of deferred tax assets and liabilities against the prior year provisional estimates as required by the Tax Cuts and Jobs Act. The increase in income tax expense was partially offset by the suspension of the non-tax deductible Health Insurance Provider Fee, or HIP Fee, for 2019, which resulted in a decrease in income tax expense of $i76. The decrease in the
effective tax rate was primarily due to the suspension of the non-tax deductible HIP Fee for 2019.
During the nine months ended September 30, 2019 and 2018, we recognized income tax expense of $1,014 and $1,200, respectively, which represent effective tax rates of i20.7%
and i26.5%, respectively. The decrease in income tax expense and effective tax rate was primarily due to the suspension of the non-tax deductible HIP Fee for 2019, which resulted in a decrease in income tax expense of $i243.
-23-
8.
i
Retirement Benefits
i
The components of net periodic benefit
credit included in our consolidated statements of income for the three months ended September 30, 2019 and 2018 are as follows:
Pension Benefits
Other
Benefits
Three Months Ended September 30
Three Months Ended September 30
2019
2018
2019
2018
Service
cost
$
i—
$
i2
$
i1
$
i—
Interest
cost
i15
i14
i3
i4
Expected
return on assets
(i35
)
(i37
)
(i6
)
(i6
)
Recognized
actuarial loss
i5
i6
i1
i1
Settlement
loss
i4
i6
i—
i—
Amortization
of prior service credit
i—
i—
(i3
)
(i3
)
Net
periodic benefit credit
$
(i11
)
$
(i9
)
$
(i4
)
$
(i4
)
The
components of net periodic benefit credit included in our consolidated statements of income for the nine months ended September 30, 2019 and 2018 are as follows:
Pension Benefits
Other
Benefits
Nine Months Ended September 30
Nine Months Ended September 30
2019
2018
2019
2018
Service
cost
$
i—
$
i6
$
i1
$
i1
Interest
cost
i47
i41
i11
i11
Expected
return on assets
(i104
)
(i110
)
(i17
)
(i18
)
Recognized
actuarial loss
i13
i18
i2
i3
Settlement
loss
i8
i19
i—
i—
Amortization
of prior service credit
i—
i—
(i9
)
(i9
)
Net
periodic benefit credit
$
(i36
)
$
(i26
)
$
(i12
)
$
(i12
)
/
For
the year ending December 31, 2019, no material contributions are expected to be necessary to meet the Employee Retirement Income Security Act of 1974, as amended, or ERISA, required funding levels; however, we may elect to make discretionary contributions up to the maximum amount deductible for income tax purposes. Contributions of $i0 and $i7
were made to our retirement benefit plans during the nine months ended September 30, 2019 and 2018.
-24-
9.iMedical
Claims Payable
i
A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2019 is as follows:
Commercial
&
Specialty
Business
Government
Business
Total
Gross medical claims payable, beginning of period
$
i2,586
$
i4,680
$
i7,266
Ceded
medical claims payable, beginning of period
(i10
)
(i24
)
(i34
)
Net
medical claims payable, beginning of period
i2,576
i4,656
i7,232
Net
incurred medical claims:
Current period
i18,986
i39,171
i58,157
Prior
periods redundancies
(i162
)
(i275
)
(i437
)
Total
net incurred medical claims
i18,824
i38,896
i57,720
Net
payments attributable to:
Current period medical claims
i16,277
i33,474
i49,751
Prior
periods medical claims
i2,213
i4,253
i6,466
Total
net payments
i18,490
i37,727
i56,217
Net
medical claims payable, end of period
i2,910
i5,825
i8,735
Ceded
medical claims payable, end of period
i8
i27
i35
Gross
medical claims payable, end of period
$
i2,918
$
i5,852
$
i8,770
At
September 30, 2019, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty Business was $i30,
$i171 and $i2,709
for the claim years 2017 and prior, 2018 and 2019, respectively.
At September 30, 2019, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was $i23,
$i105 and $i5,697
for the claim years 2017 and prior, 2018 and 2019, respectively.
/
-25-
A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2018 is as follows:
Commercial
&
Specialty
Business
Government
Business
Total
Gross medical claims payable, beginning of period
$
i3,383
$
i4,431
$
i7,814
Ceded
medical claims payable, beginning of period
(i78
)
(i27
)
(i105
)
Net
medical claims payable, beginning of period
i3,305
i4,404
i7,709
Business
combinations and purchase adjustments
i—
i199
i199
Net
incurred medical claims:
Current period
i17,732
i33,664
i51,396
Prior
periods redundancies
(i424
)
(i434
)
(i858
)
Total
net incurred medical claims
i17,308
i33,230
i50,538
Net
payments attributable to:
Current period medical claims
i15,275
i29,236
i44,511
Prior
periods medical claims
i2,671
i3,833
i6,504
Total
net payments
i17,946
i33,069
i51,015
Net
medical claims payable, end of period
i2,667
i4,764
i7,431
Ceded
medical claims payable, end of period
i10
i27
i37
Gross
medical claims payable, end of period
$
i2,677
$
i4,791
$
i7,468
i
The
reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2019 are as follows:
Net
incurred medical claims for the three months ended March 31, 2019 and June 30, 2019 in the table above include a reclassification between the Commercial and Specialty Business and Government Business segments to adjust certain intercompany eliminations. This reclassification did not impact any other amounts presented in the consolidated financial statements.
/
-26-
The reconciliation of net incurred medical claims to benefit expense
included in our consolidated statements of income for periods in 2018 are as follows:
The
reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of September 30, 2019, is as follows:
Commercial
& Specialty
Business
Government
Business
Total
Net
medical claims payable, end of period
$
i2,910
$
i5,825
$
i8,735
Ceded
medical claims payable, end of period
i8
i27
i35
Insurance
lines other than short duration
i—
i207
i207
Gross
medical claims payable, end of period
$
i2,918
$
i6,059
$
i8,977
/
10.
i
Debt
We
generally issue senior unsecured notes for long-term borrowing purposes. At September 30, 2019 and December 31, 2018, we had $i18,816 and $i17,153,
respectively, outstanding under these notes.
On September 9, 2019, we issued $i850 aggregate principal amount of i2.375%
Notes due 2025, or the 2025 Notes, $i825 aggregate principal amount of i2.875%
Notes due 2029, or the 2029 Notes, and $i825 aggregate principal amount of i3.700%
Notes due 2049, or the 2049 Notes, under our shelf registration statement. Interest on the 2025 Notes is payable semi-annually in arrears on January 15 and July 15 of each year, commencing January 15, 2020. Interest on the 2029 Notes and the 2049 Notes is payable semi-annually in arrears on March 15 and September 15 each year, commencing March 15, 2020. The proceeds are being used for working capital and general corporate purposes, including, but not limited to, the repurchase of our common stock pursuant to our share repurchase program, repayment of short-term and long-term debt and to fund acquisitions.
On May 1, 2018, we settled each of the Equity Units stock purchase contracts at a
settlement rate of i0.2412 shares of our common stock, using a market value formula set forth in the Equity Units purchase contracts. This resulted in the issuance of approximately i6.0
shares. We had issued i25 Equity Units on May 12, 2015, pursuant to an underwriting agreement dated May 6, 2015, in an aggregate principal amount of $i1,250.
Each Equity Unit had a stated amount of $i50 (whole dollars) and consisted of a purchase contract obligating the holder to purchase a certain number of shares of our common stock on May 1, 2018, subject to earlier termination or settlement, for a price in cash of $50 (whole dollars); and a i5%
undivided beneficial ownership interest in $i1,000 (whole dollars) principal amount of our i1.900%
remarketable subordinated notes, or RSNs, due 2028. On March 2, 2018, we remarketed the RSNs and used the proceeds to purchase U.S. Treasury securities that were pledged to secure the stock purchase obligations of the holders of the Equity Units. The purchasers of the RSNs transferred the RSNs to us in exchange for $i1,250
principal amount of our 4.101% senior notes due 2028, or the 2028 Notes, and a cash payment of $i4. We cancelled the RSNs upon receipt and recognized a loss on extinguishment of debt of $i18.
At the remarketing, we also issued $i850aggregate principal amount of 4.550% notes due 2048, or the 2048 Notes, under our shelf registration statement.We used the proceeds from the 2048 Notes for working capital and general corporate purposes. Interest on the 2028 Notes and
the 2048 Notes is payable semi-annually in arrears on March 1 and September 1 of each year, commencing on September 1, 2018.
We have a senior revolving credit facility, or the 5-Year Facility, with a group of lenders for general corporate purposes. In June 2019, we amended and restated the credit agreement for the 5-Year Facility to, among other things, extend the maturity date of the 5-Year Facility from August 2020 to June 2024 and decreased the amount of credit available under the 5-Year Facility from $i3,500
to $i2,500. In June 2019, we also entered into a 364-day senior revolving credit facility, or 364-Day Facility, with a group of lenders for general corporate purposes, which provides for credit in the amount of $i1,000
and matures in June 2020. There were no amounts outstanding under the 5-Year Facility or the 364-Day Facility at any time during the nine months endedSeptember 30, 2019 or under the 5-Year Facility at December 31, 2018.
Through certain subsidiaries, we have entered into multiple 364-day lines of credit, or the Subsidiary Credit Facilities, with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit of up to $i600.
At September 30, 2019 and December 31, 2018, $i150 and $i500,
respectively, were outstanding under our Subsidiary Credit Facilities.
We have an authorized commercial paper program of up to $i3,500, the proceeds of which may be used for general corporate purposes. In August 2019, we increased the amount available under the commercial paper program from $i2,500
to $i3,500. At September 30, 2019 and December 31, 2018, we had $i500
and $i697, respectively, outstanding under this program.
We have outstanding senior unsecured convertible debentures due 2042, or the Debentures, which are governed by an indenture between us and The Bank of New York Mellon Trust Company, N.A., as trustee, or the indenture. We have accounted for
the Debentures in accordance with the FASB cash conversion guidance for debt with conversion and other options. As a result, the value of the embedded conversion option (net of deferred taxes and equity issuance costs) has been bifurcated from its debt host and recorded as a component of additional paid-in capital in our consolidated balance sheets. During the nine months endedSeptember 30, 2019, $i20
aggregate principal amount of the Debentures were surrendered for conversion by certain holders in accordance with the terms and provisions of the indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments of $i73. We recognized a gain of $i1
on the extinguishment of debt related to the Debentures, based on the fair values of the debt on the conversion settlement dates.
i
The following table summarizes at September 30, 2019 the related balances, conversion rate and conversion price of the Debentures:
Outstanding principal amount
$
i267
Unamortized
debt discount
$
i85
Net debt carrying amount
$
i179
Equity
component carrying amount
$
i97
Conversion rate (shares of common stock per $1,000 of principal amount)
i13.9250
Effective
conversion price (per $1,000 of principal amount)
$
i71.8129
/
We are
a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati and the Federal Home Loan Bank of Atlanta, or collectively, the FHLBs. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $i560
and $i645 in outstanding short-term borrowings from FHLBs, at September 30, 2019 and December 31, 2018 with fixed interest rates of i1.990%
and i2.458% respectively.
All debt is a direct obligation of Anthem, Inc., except for the surplus note, the FHLB borrowings, and the Subsidiary Credit Facilities.
-28-
11.
iCommitments and Contingencies
Litigation and Regulatory Proceedings
In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below,
we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss.
With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses
in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves is, in the aggregate, from $i0
to approximately $i700 at September 30, 2019. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in
multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees, or Blue plans, across the country. The cases were consolidated into a single multi-district proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation that is pending in the United States District Court for the Northern District of Alabama, or the Court. Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions rules governing the BlueCard and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act, or Sherman Act, and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers, and actions filed
in twenty-eight states have been consolidated into the multi-district proceeding.
In response to cross motions for partial summary judgment by plaintiffs and defendants, the Court issued an order in April 2018 determining that the defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. The Court also found that there remain genuine issues of material fact as to whether defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks. No dates have been set for either the final pretrial conferences or trials in these actions. In March 2019, the Court issued a Fourth Amended Scheduling Order requiring that briefing on motions for class certification and related expert
reports, merits and damages expert reports, and certain dispositive motions occur in 2019. In April 2019, plaintiffs filed their motions for class certification in conjunction with their supporting expert reports. Defendants filed their motions to exclude plaintiffs’ experts, as well as their opposition to plaintiffs’ motions for class certification, in July 2019. The case has been stayed until January 2020. We intend to vigorously defend these suits; however, their ultimate outcome cannot be presently determined.
-29-
Blue Cross of California Taxation Litigation
In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue
Cross), or BCC, was named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court, captioned Michael D. Myers v. State Board of Equalization, et al. This action was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, or HCSP, is an “insurer” for purposes of taxation despite acknowledging it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were required to pay a gross premiums tax, or GPT, calculated as i2.35%
on gross premiums. As a licensed HCSP, BCC has paid the California Corporate Franchise Tax, or CFT, the tax paid by California businesses generally. Plaintiff contends that BCC must pay the GPT rather than the CFT, and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint.
In March 2018, the Superior Court denied BCC’s motion for judgment on the pleadings and similar motions brought by other entities. We filed a writ of mandate in the California Court of Appeal. Although the California Court of Appeal initially accepted our writ, it later indicated that it will not hear the issues raised by our writ until the case concludes in the Superior Court. The Superior Court has scheduled trial for March 23, 2020. The parties are currently
engaged in discovery and are in the process of retaining experts. Because GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax periods at issue in the litigation. BCC intends to vigorously defend this suit; however, its ultimate outcome cannot be presently determined.
Express Scripts, Inc. Pharmacy Benefit Management Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc., or Express Scripts, our vendor for pharmacy benefit management, or PBM, services, captioned Anthem, Inc. v. Express Scripts, Inc., in the U.S. District
Court for the Southern District of New York. The lawsuit seeks to recover over $i14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties, or ESI PBM Agreement, over $i158
in damages related to operational breaches, as well as various declarations under the ESI PBM Agreement between the parties, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) is required to provide competitive benchmark pricing to us through the term of the ESI PBM Agreement; (iii) has breached the ESI PBM Agreement; and (iv) is required under the ESI PBM Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination.
Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI PBM Agreement; and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI PBM Agreement and that its
sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly enriched by its payment of $i4,675 at the time we entered into the ESI PBM Agreement. In March 2017, the court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. The only remaining claims are for breach
of contract and declaratory relief. Discovery is scheduled to be completed in December 2019. We intend to vigorously pursue our claims and defend against any counterclaims, which we believe are without merit; however, the ultimate outcome cannot be presently determined.
In re Express Scripts/Anthem ERISA Litigation
We are a defendant in a class action lawsuit that was initially filed in June 2016 against Anthem, Inc. and Express Scripts, which has been consolidated into a single multi-district lawsuit captioned In Re Express Scripts/Anthem ERISA Litigation, in the U.S. District Court for the Southern District of New York. The consolidated complaint was filed by plaintiffs against Express Scripts and us on behalf of all persons who are participants
in or beneficiaries of any ERISA or non-ERISA healthcare plan from December 1, 2009 to the present in which we provided prescription drug benefits through the ESI PBM Agreement and paid a percentage based co-insurance payment in the course of using that prescription drug benefit. The plaintiffs allege that we breached our duties, either under ERISA or with respect to the implied covenant of good faith and fair dealing implied in the health plans, (i) by failing to adequately monitor Express Scripts’ pricing under the ESI
-30-
PBM Agreement and (ii) by placing our own pecuniary interest above the best interests of our insureds by allegedly agreeing to higher
pricing in the ESI PBM Agreement in exchange for the purchase price for our NextRx PBM business, and (iii) with respect to the non-ERISA members, by negotiating and entering into the ESI PBM Agreement that was allegedly detrimental to the interests of such non-ERISA members. Plaintiffs seek to hold us and Express Scripts jointly and severally liable and to recover all losses suffered by the proposed class, equitable relief, disgorgement of alleged ill-gotten gains, injunctive relief, attorney’s fees and costs and interest.
In April 2017, we filed a motion to dismiss the claims brought against us, and it was granted, without prejudice, in January 2018. Plaintiffs filed a notice of appeal with the United States Court of Appeals for the Second Circuit, which was heard in October 2018 but has not yet been decided. We intend to vigorously defend this suit; however, its ultimate outcome cannot be presently determined.
Cigna
Corporation Merger Litigation
In July 2015, we and Cigna Corporation, or Cigna, announced that we entered into the Agreement and Plan of Merger, or Cigna Merger Agreement, pursuant to which we would acquire all outstanding shares of Cigna. In July 2016, the U.S. Department of Justice, or DOJ, along with certain state attorneys general, filed a civil antitrust lawsuit in the U.S. District Court for the District of Columbia, or District Court, seeking to block the merger. In February 2017, Cigna purported to terminate the Cigna Merger Agreement and commenced litigation against us in the Delaware Court of Chancery, or Delaware Court, seeking damages, including the $i1,850
termination fee pursuant to the terms of the Cigna Merger Agreement, and a declaratory judgment that its purported termination of the Cigna Merger Agreement was lawful, among other claims, which is captioned Cigna Corp. v. Anthem Inc.
Also in February 2017, we initiated our own litigation against Cigna in the Delaware Court seeking a temporary restraining order to enjoin Cigna from terminating the Cigna Merger Agreement, specific performance compelling Cigna to comply with the Cigna Merger Agreement and damages, which is captioned Anthem Inc. v. Cigna Corp. In April 2017, the U.S. Circuit Court of Appeals for the District of Columbia affirmed the ruling of the District Court, which blocked the merger. In May 2017, after the Delaware Court denied our motion to enjoin Cigna from terminating the Cigna Merger Agreement, we delivered to
Cigna a notice terminating the Cigna Merger Agreement.
In the Delaware Court litigation, trial commenced in late February 2019 and concluded in March 2019. The Delaware Court has set closing argument for November 25, 2019. We believe Cigna’s allegations are without merit and we intend to vigorously pursue our claims and defend against Cigna’s allegations; however, the ultimate outcome of our litigation with Cigna cannot be presently determined.
In October 2018, a shareholder filed a derivative lawsuit in the State of Indiana Marion County Superior Court, captioned Henry Bittmann, Derivatively, et al. v. Joseph R Swedish, et al., purportedly on behalf of us and our shareholders against certain current and former directors and officers alleging breaches of fiduciary duties, unjust enrichment
and corporate waste associated with the Cigna Merger Agreement. This case has been stayed at the request of the parties pending the outcome of our litigation with Cigna in the Delaware Court. This lawsuit’s ultimate outcome cannot be presently determined.
U.S. Department of Justice (DOJ) Civil Investigative Demands
Beginning in December 2016, the DOJ has issued civil investigative demands to us to discover information about our chart review and risk adjustment programs under Parts C and D of the Medicare Program. We understand the DOJ is investigating the programs of other Medicare Advantage health plans, along with providers and vendors. We continue to cooperate with the DOJ’s investigation, and the ultimate outcome cannot presently be determined.
Cyber Attack Regulatory Proceedings and Litigation
In
February 2015, we reported that we were the target of a sophisticated external cyber attack. The attackers gained unauthorized access to certain of our information technology systems and obtained personal information related to many individuals and employees, such as names, birth dates, healthcare identification/social security numbers, street addresses, email addresses, phone numbers and employment information, including income data. To date, there is no evidence that
-31-
credit card or medical information, such as claims, test results or diagnostic codes, were targeted, accessed or obtained, although no assurance can be given that we will not identify additional information that was accessed or obtained.
Upon
discovery of the cyber attack, we took immediate action to remediate the security vulnerability and retained a cybersecurity firm to evaluate our systems and identify solutions based on the evolving landscape. We have provided credit monitoring and identity protection services to those who have been affected by this cyber attack. We have continued to implement security enhancements since this incident. We have incurred expenses subsequent to the cyber attack to investigate and remediate this matter and expect to continue to incur expenses of this nature in the foreseeable future. We recognize these expenses in the periods in which they are incurred.
Federal and state agencies, including state insurance regulators, state attorneys general, the Health and Human Services Office of Civil Rights and the Federal Bureau of Investigation, are investigating, or have investigated, events related to the cyber attack, including how it
occurred, its consequences and our responses. The investigations have all been resolved with the exception of an ongoing investigation by a multi-state group of attorneys general, which remains outstanding. Although we are cooperating in this investigation, we may be subject to additional fines or other obligations. We intend to vigorously defend the remaining regulatory investigation; however, its ultimate outcome cannot be presently determined.
We have contingency plans and insurance coverage for certain expenses and potential liabilities of this nature and will pursue coverage for all applicable losses; however, the ultimate outcome of our pursuit of insurance coverage cannot be presently determined.
Other Contingencies
From time to time, we and certain of our subsidiaries
are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like HMOs and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, PPO and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.
In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business, and are from time to time involved as
a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.
Contractual Obligations and Commitments
Express Scripts, through our ESI PBM Agreement, is the provider of certain PBM services to our plans. In
October 2017, we established a new pharmacy benefits manager, called IngenioRx, and entered into a five-year agreement with CaremarkPCS Health, L.L.C., or CVS Health, which is a subsidiary of CVS Health Corporation, to begin offering PBM solutions, or the CVS PBM Agreement. In January 2019, we exercised our contractual right to terminate the ESI PBM Agreement earlier than the original expiration date of December 31, 2019 due to the recent acquisition of Express Scripts by Cigna. As a result of exercising our early termination right, the ESI PBM Agreement terminated on March 1, 2019, and on March 2, 2019, the twelve-month transition period to migrate the services from Express Scripts began. CVS Health began providing certain PBM services to IngenioRx pursuant to the CVS PBM Agreement in the second quarter of 2019. Notwithstanding
our termination of the ESI PBM Agreement, the litigation between us and Express Scripts regarding the ESI PBM Agreement continues. For additional information regarding this lawsuit, refer to the Litigation and Regulatory Proceedings-Express Scripts, Inc. Pharmacy Benefit Management Litigation section above. We believe we have appropriately recognized all rights and obligations under the ESI PBM Agreement as of September 30, 2019.
-32-
12.
iCapital Stock
Use of Capital – Dividends and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements
and other factors deemed relevant by our Board of Directors.
i
A summary of the cash dividend activity for the nine months ended September 30, 2019 and 2018 is as follows:
On
October 22, 2019, our Audit Committee declared a fourth quarter 2019 dividend to shareholders of $i0.80 per share, payable on iDecember
20, 2019 to shareholders of record at the close of business on iDecember 5, 2019.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On December 7, 2017, the Board of Directors authorized a $i5,000
increase to the common stock repurchase program. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.
For
additional information regarding the use of capital for debt security repurchases, see Note 10, “Debt” of this Form 10-Q and Note 12, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31, 2018 included in our 2018 Annual Report on Form 10-K.
-33-
Stock Incentive Plans
i
A
summary of stock option activity for the nine months ended September 30, 2019 is as follows:
During
the nine months ended September 30, 2019, we granted approximately i0.2 restricted stock units that are contingent upon us achieving earnings targets over the three year period from 2019 to 2021.
These grants have been included in the activity shown above, but will be subject to adjustment at the end of 2021 based on results in the three year period.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair value methodology, see Note 14, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended December 31, 2018 included in our 2018 Annual Report on Form 10-K.
i
The
following weighted-average assumptions were used to estimate the fair values of options granted during the nine months ended September 30, 2019 and 2018:
Nine Months Ended September 30
2019
2018
Risk-free
interest rate
i2.69
%
i2.90
%
Volatility
factor
i25.00
%
i30.00
%
Quarterly
dividend yield
i0.260
%
i0.323
%
Weighted-average
expected life (years)
i4.40
i3.70
/
-34-
i
The
following weighted-average fair values per option or share were determined for the nine months ended September 30, 2019 and 2018:
Nine Months Ended September 30
2019
2018
Options
granted during the period
$
i68.69
$
i55.44
Restricted
stock awards granted during the period
i306.13
i233.27
/
13.
i
Accumulated Other Comprehensive Loss
i
A reconciliation of the components of accumulated other comprehensive loss at September 30, 2019 and 2018 is as follows:
September
30
2019
2018
Investments, excluding non-credit component of other-than-temporary impairments:
Gross unrealized gains
$
i770
$
i170
Gross
unrealized losses
(i54
)
(i289
)
Net
pre-tax unrealized gains (losses)
i716
(i119
)
Deferred
tax (liability) asset
(i164
)
i24
Net
unrealized gains (losses) on investments
i552
(i95
)
Non-credit
components of other-than-temporary impairments on investments:
Unrealized losses
(i5
)
(i2
)
Deferred
tax asset
i1
i—
Net
unrealized non-credit component of other-than-temporary impairments on investments
(i4
)
(i2
)
Cash
flow hedges:
Gross unrealized losses
(i340
)
(i315
)
Deferred
tax asset
i63
i66
Net
unrealized losses on cash flow hedges
(i277
)
(i249
)
Defined
benefit pension plans:
Deferred net actuarial loss
(i730
)
(i587
)
Deferred
prior service credits
(i1
)
(i1
)
Deferred
tax asset
i188
i153
Net
unrecognized periodic benefit costs for defined benefit pension plans
(i543
)
(i435
)
Postretirement
benefit plans:
Deferred net actuarial loss
(i57
)
(i75
)
Deferred
prior service costs
i25
i37
Deferred
tax asset
i8
i10
Net
unrecognized periodic benefit costs for postretirement benefit plans
(i24
)
(i28
)
Foreign
currency translation adjustments:
Gross unrealized losses
(i4
)
(i2
)
Deferred
tax asset
i1
i—
Net
unrealized losses on foreign currency translation adjustments
(i3
)
(i2
)
Accumulated
other comprehensive loss
$
(i299
)
$
(i811
)
/
-35-
i
Other
comprehensive income (loss) reclassification adjustments for the three months ended September 30, 2019 and 2018 are as follows:
Three Months Ended September 30
2019
2018
Investments:
Net
holding gain (loss) on investment securities arising during the period, net of tax (expense) benefit of ($35) and $12, respectively
$
i119
$
(i45
)
Reclassification
adjustment for net realized (gain) loss on investment securities, net of tax expense (benefit) of $1 and ($3), respectively
(i3
)
i9
Total
reclassification adjustment on investments
i116
(i36
)
Non-credit
component of other-than-temporary impairments on investments:
Non-credit component of other-than-temporary impairments on investments, net of tax expense of ($0) and ($2), respectively
(i1
)
(i2
)
Cash
flow hedges:
Holding (loss) gain, net of tax expense of ($2) and ($1), respectively
(i34
)
i2
Other:
Net
change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, net of tax expense of ($1) and ($2), respectively
i4
i7
Foreign
currency translation adjustment, net of tax expense of ($0) and ($0), respectively
(i1
)
i—
Net
gain (loss) recognized in other comprehensive income, net of tax (expense) benefit of ($37) and $4, respectively
$
i84
$
(i29
)
Other
comprehensive income (loss) reclassification adjustments for the nine months ended September 30, 2019 and 2018 are as follows:
Nine Months Ended September 30
2019
2018
Investments:
Net
holding gain (loss) on investment securities arising during the period, net of tax (expense) benefit of ($205) and $109, respectively
$
i705
$
(i378
)
Reclassification
adjustment for net realized (gain) loss on investment securities, net of tax benefit of $(1) and $(7), respectively
i6
i25
Total
reclassification adjustment on investments
i711
(i353
)
Non-credit
component of other-than-temporary impairments on investments:
Non-credit component of other-than-temporary impairments on investments, net of tax expense of ($0) and ($2), respectively
(i2
)
(i2
)
Cash
flow hedges:
Holding (loss) gain, net of tax expense of ($2) and ($9), respectively
(i31
)
i34
Other:
Net
change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, net of tax expense of ($3) and ($7), respectively
i10
i22
Foreign
currency translation adjustment, net of tax expense of ($0) and ($1), respectively
(i1
)
i—
Net
gain (loss) recognized in other comprehensive income, net of tax (expense) benefit of ($211) and $83, respectively
$
i687
$
(i299
)
/
-36-
14.
iEarnings per Share
i
The denominator for basic and diluted earnings per share for the three and nine months ended September 30,
2019 and 2018 is as follows:
Three Months Ended September 30
Nine Months Ended September 30
2019
2018
2019
2018
Denominator
for basic earnings per share – weighted-average shares
i255.2
i259.5
i256.3
i258.0
Effect
of dilutive securities – employee stock options, nonvested restricted stock awards, convertible debentures and equity units
i4.8
i5.9
i4.8
i6.3
Denominator
for diluted earnings per share
i260.0
i265.4
i261.1
i264.3
/
During
the three months ended September 30, 2019 and 2018, weighted-average shares related to certain stock options of i0.7 and i0.0,
respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. During each of the nine months ended September 30, 2019 and 2018, weighted-average shares related to certain stock options of i0.6
and i0.4, respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive.
During the three and nine months ended September 30, 2019, we issued approximately i0.0
and i0.5 restricted stock units under our stock incentive plans, i0.2
of which vesting is contingent upon us meeting specified annual earnings targets for the three year period of 2019 through 2021. During the three and nine months endedSeptember 30, 2018, we issued approximately i0.0
and i0.9 restricted stock units under our stock incentive plans, i0.3
of which vesting is contingent upon us meeting specified annual earnings targets for the three year period of 2018 through 2020. The contingent restricted stock units have been excluded from the denominator for diluted earnings per share and will be included only if and when the contingency is met.
15.
i
Segment
Information
The results of our operations are described through ithree reportable segments: Commercial & Specialty Business, Government Business and Other, as further described in Note 19, “Segment Information,” to our audited consolidated financial statements as of and for the year ended December 31, 2018 included in our 2018
Annual Report on Form 10-K.
Prior to the second quarter of 2019, our Other segment included certain eliminations and corporate expenses not allocated to either of our other reportable segments. Beginning in the second quarter of 2019, our Other segment also includes IngenioRx, our PBM, which began its operations during the second quarter of 2019. In addition, during the second quarter, we reclassified our Diversified Business Group, or DBG, our integrated health services business, from our Government Business segment to the Other segment to reflect changes in how our segments are being managed. Amounts for 2018 have been reclassified to conform to the current year presentation for comparability. Based on the FASB guidance, as of September 30, 2019, IngenioRx and DBG do not collectively meet the quantitative thresholds for an operating
segment.
Affiliated revenues represent revenues or cost for services provided by IngenioRx and DBG to our subsidiaries, are recorded at cost or management’s estimate of fair market value, and are eliminated in consolidation.
For our segment reporting, operating gains (losses) generated from IngenioRx and DBG affiliated activity have been included in our Commercial & Specialty Business and Government Business based upon their utilization of services from IngenioRx and DBG.
-37-
i
Financial
data by reportable segment for the three and nine months ended September 30, 2019 and 2018 is as follows:
The
major product revenues for each of the reportable segments for the three and nine months ended September 30, 2019 and 2018 are as follows:
Three Months Ended September
30
Nine Months Ended September 30
2019
2018
2019
2018
Commercial & Specialty Business
Managed
care products
$
i7,542
$
i7,211
$
i22,806
$
i21,852
Managed
care services
i1,330
i1,332
i4,049
i3,913
Dental/Vision
products and services
i325
i306
i975
i914
Other
i87
i84
i263
i260
Total
Commercial & Specialty Business
i9,284
i8,933
i28,093
i26,939
Government
Business
Managed care products
i15,847
i13,860
i46,111
i40,610
Managed
care services
i108
i119
i308
i341
Total
Government Business
i15,955
i13,979
i46,419
i40,951
Other
Other
i2,508
i398
i3,850
i1,108
Eliminations
Eliminations
(i1,303
)
(i330
)
(i2,353
)
(i961
)
Total
product revenues
$
i26,444
$
i22,980
$
i76,009
$
i68,037
/
The
classification between managed care products and managed care services in the above table primarily distinguishes between the levels of risk assumed. Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent product offerings where we provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk.
-38-
i
A
reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and nine months ended September 30, 2019 and 2018 is as follows:
Three
Months Ended September 30
Nine Months Ended September 30
2019
2018
2019
2018
Reportable segments’ operating revenue
$
i26,444
$
22,980
$
i76,009
$
68,037
Net
investment income
i242
i250
i737
i708
Net
realized gains on financial instruments
i1
i27
i90
i5
Other-than-temporary
impairment losses recognized in income
(i13
)
(i6
)
(i30
)
(i18
)
Total
revenues
$
i26,674
$
i23,251
$
i76,806
$
i68,732
/i
A
reconciliation of reportable segments’ operating gain to income before income tax expense included in our consolidated statements of income for the three and nine months ended September 30, 2019 and 2018 is as follows:
Three
Months Ended September 30
Nine Months Ended September 30
2019
2018
2019
2018
Reportable segments’ operating gain
$
i1,528
$
i1,249
$
i4,901
$
i4,676
Net
investment income
i242
i250
i737
i708
Net
realized gains on financial instruments
i1
i27
i90
i5
Other-than-temporary
impairment losses recognized in income
(i13
)
(i6
)
(i30
)
(i18
)
Interest
expense
(i185
)
(i188
)
(i556
)
(i564
)
Amortization
of other intangible assets
(i84
)
(i91
)
(i256
)
(i265
)
Gain
(loss) on extinguishment of debt
i—
i1
i1
(i17
)
Income
before income tax expense
$
i1,489
$
i1,242
$
i4,887
$
i4,525
/
-39-
16.
iLeases
We lease office space and certain computer and related equipment using noncancelable operating leases. Our leases have remaining lease terms of i1
year to i15 years.
i
The information related to our leases is as follows:
As of September 30, 2019,
we have additional operating leases for building spaces that have not yet commenced, and some building spaces are being constructed by the lessors and their agents. These leases have terms of up to i12 years and iare
expected to commence on various dates during 2020 and 2021 when the construction is complete and we take possession of the buildings. The undiscounted lease payments for these leases, which are not included in the tables above, aggregate $i147.
-40-
ITEM
2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(In Millions, Except Per Share Data or as Otherwise Stated Herein)
This Management’s Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, should be read in conjunction with the accompanying consolidated financial statements and notes, our consolidated financial statements and notes as of and for the year ended December 31, 2018 and the MD&A included in our 2018 Annual Report on Form 10-K. References to the terms “we,”“our,”“us,” or “Anthem” used throughout this MD&A refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries.
References to the “states” include the District of Columbia, unless the context otherwise requires.
Results of operations, cost of care trends, investment yields and other measures for the three and nine months ended September 30, 2019 are not necessarily indicative of the results and trends that may be expected for the full year ending December 31, 2019, or any other period.
Overview
We are one of the largest health benefits companies in the United States in terms of medical membership,
serving approximately 41medical members through our affiliated health plans as of September 30, 2019. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through
arrangements with other BCBS licensees. Through our subsidiaries, we serve customers in numerous states across the country as America’s 1st Choice, Amerigroup, Aspire Health, CareMore, Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply Healthcare, and/or Unicare. Also, beginning in the second quarter of 2019, we provide pharmacy benefits management services through our IngenioRx subsidiary. We are licensed to conduct insurance operations in all 50 states and the District of Columbia through our subsidiaries.
For additional information about our organization, see Part I, Item 1, “Business” and Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results
of Operations,” included in our 2018 Annual Report on Form 10-K. Additional information on our segments can be found in this MD&A and in Note 15, “Segment Information” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Business Trends
The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended, or collectively, the ACA, has changed and may continue to make broad-based changes to the U.S. health care system, which we expect will continue to impact our business model and strategy. Also, the legal challenges regarding the ACA, including the ultimate outcome of the December 2018 decision of the U.S. District Court for the Northern District of Texas,
Fort Worth Division invalidating the ACA, or the 2018 Texas District Court ACA Decision, which judgment has been stayed pending appeal, could significantly disrupt our business. During 2018, we strategically reduced our participation in the Individual ACA-compliant market. Our strategy has been, and will continue to be, to only participate in rating regions where we have an appropriate level of confidence that these markets are on a path toward sustainability, including, but not limited to, factors such as expected financial performance, regulatory environment, and underlying market characteristics. We currently offer Individual ACA-compliant products in 73 of the 143 rating regions in which we operate.
In October 2017, we established a new pharmacy benefits manager, or PBM, called IngenioRx, and entered into a five-year agreement with CaremarkPCS Health, L.L.C., or CVS Health, which is a subsidiary of CVS Health Corporation,
to begin offering PBM solutions (the “CVS PBM Agreement”) upon the conclusion of our PBM agreement with Express Scripts Inc., or Express Scripts (the “ESI PBM Agreement”). As a result of exercising our early termination right, the ESI PBM Agreement terminated on March 1, 2019, and on March 2, 2019, the twelve-month transition period to migrate the services from Express Scripts began. CVS Health began providing certain PBM services to IngenioRx in the second quarter of 2019
-41-
pursuant to the CVS PBM Agreement. We expect IngenioRx to provide our members with more cost-effective solutions and
improve our ability to integrate pharmacy benefits within our medical and specialty platform.
Pricing Trends: We strive to price our healthcare benefit products consistent with anticipated underlying medical trends. We frequently make adjustments to respond to legislative and regulatory changes as well as pricing and other actions taken by existing competitors and new market entrants. Product pricing in our Commercial & Specialty Business segment, including our Individual and Small Group lines of business, remains competitive. Revenues from the Medicare and Medicaid programs are dependent, in whole or in part, upon annual funding from the federal government and/or applicable state governments.
The ACA imposed an annual Health Insurance Provider Fee, or HIP Fee, on health insurers that write certain types of health insurance on U.S. risks. We price our affected
products to cover the impact of the HIP Fee. The HIP Fee was suspended for 2019 and is scheduled to resume for 2020.
Medical Cost Trends: Our medical cost trends are primarily driven by increases in the utilization of services across all provider types and the unit cost increases of these services. We work to mitigate these trends through various medical management programs such as utilization management, condition management, program integrity and specialty pharmacy management, as well as benefit design changes. There are many drivers of medical cost trends which can cause variances from our estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the population, health status and other demographic characteristics of our members, epidemics, advances in medical technology, new high cost prescription drugs, and healthcare provider or member fraud. Our underlying
Local Group medical cost trends reflect the “allowed amount,” or contractual rate, paid to providers. We estimate that the 2019 Local Group medical cost trend will be in the range of 5.5% to 6.5%.
For additional discussion regarding business trends, see Part I, Item 1, “Business” included in our 2018 Annual Report on Form 10-K.
Regulatory Trends and Uncertainties
The ACA presented us with new growth opportunities, but also introduced new risks, regulatory challenges and uncertainties, and required changes in the way products are designed, underwritten, priced, distributed and administered. Changes to our business environment may continue for the next several years as elected officials at the national and state levels continue to propose significant modifications to existing laws and regulations, including the reduction of the
individual mandate penalty to zero, effective January 1, 2019, elimination of funding for cost-sharing subsidies made available for qualified individuals, and changes to taxes and fees. In addition, the legal challenges regarding the ACA, including the ultimate outcome of the 2018 Texas District Court ACA Decision, continue to contribute to this uncertainty. We will continue to evaluate the impact of the ACA as additional guidance is made available and any further developments or judicial rulings occur.
The annual HIP Fee is allocated to health insurers based on the ratio of the amount of an insurer’s net premium revenues written during the preceding calendar year to the amount of health insurance premium for all U.S. health risk for those certain lines of business written during the preceding calendar year. We record our estimated liability for the HIP Fee in full at the beginning
of the year with a corresponding deferred asset that is amortized on a straight-line basis to selling, general and administrative expense. The final calculation and payment of the annual HIP Fee is due by September 30th of each fee year. The HIP Fee is non-deductible for federal income tax purposes. We price our affected products to cover the increased selling, general and administrative and income tax expenses associated with the HIP Fee. The total amount due from allocations to health insurers was $14,300 for 2018. For the three and nine months ended September 30, 2018, we recognized $362 and $1,157, respectively, as general
and administrative expense related to the HIP Fee. There was no corresponding expense for 2019 due to the suspension of the HIP Fee for 2019. The HIP Fee is scheduled to resume for 2020.
For additional discussion regarding regulatory trends and uncertainties and risk factors, see Part I, Item 1, “Business - Regulation” and Part I, Item 1A, “Risk Factors”, and the “Regulatory Trends and Uncertainties” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2018 Annual Report on Form 10-K.
-42-
Other Significant Items
In
June 2019, we announced our entrance into an agreement to acquire Beacon Health Options, Inc., or Beacon, the largest independently held behavioral health organization in the country. Beacon serves approximately forty million individuals across all fifty states. This acquisition aligns with our strategy to diversify into health services and deliver both integrated solutions and care delivery models that personalize care for people with complex and chronic conditions. The acquisition is expected to close late in the fourth quarter of 2019 and is subject to standard closing conditions and customary approvals.
In October 2017, we established IngenioRx and entered into the CVS PBM Agreement, which coincides with the conclusion of the ESI PBM Agreement. We exercised our contractual right and terminated the ESI PBM Agreement on March 1, 2019. The twelve-month transition period to
migrate the services from Express Scripts began on March 2, 2019. CVS Health began providing certain PBM services to IngenioRx in the second quarter of 2019 pursuant to the CVS PBM Agreement. Notwithstanding our termination of the ESI PBM Agreement, the litigation between us and Express Scripts regarding the ESI PBM Agreement continues. For additional information regarding this lawsuit, see Note 11, “Commitments and Contingencies - Litigation and Regulatory Proceedings - Express Scripts, Inc. Pharmacy Benefit Management Litigation,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
In February 2018, we completed our acquisition of Freedom Health, Inc., Optimum HealthCare, Inc., America’s 1st Choice of South Carolina, Inc. and related entities, or collectively, America’s 1st Choice, a
Medicare Advantage organization that offers health maintenance organization products, including Chronic Special Needs Plans and Dual-Eligible Special Needs Plans under its Freedom Health and Optimum HealthCare brands in Florida and its America’s 1st Choice of South Carolina brand in South Carolina. For additional information, see Note 3, “Business Acquisitions,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
In May 2017, we announced that we were terminating the Agreement and Plan of Merger, or Merger Agreement, between us and Cigna Corporation. For additional information about ongoing litigation related to the Merger Agreement, see Note 11, “Commitments and Contingencies - Litigation and Regulatory Proceedings - Cigna Corporation Merger Litigation,”
of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Selected Operating Performance
For the twelve months ended September 30, 2019, total medical membership increased1.1, or 2.7%. Our medical membership grew across our reportable business segments. The increase in medical membership in our Government Business segment was primarily due to growth in our Medicaid and Medicare businesses. The increase in medical membership in our Commercial & Specialty Business segment was primarily due to growth in our National business.
Operating revenue for the three
months ended September 30, 2019 was $26,444, an increase of $3,464, or 15.1%, from the three months ended September 30, 2018. The increase in operating revenue for the three months ended September 30, 2019 compared to 2018 was primarily driven by higher premiums in our Government Business segment and increased administrative fees and other revenue in our Other segment. Operating revenue for the nine months ended September 30, 2019 was
$76,009, an increase of $7,972, or 11.7%, from the nine months ended September 30, 2018. The increase in operating revenue for the nine months ended September 30, 2019 compared to 2018 was primarily a result of higher premiums in our Government Business segment and, to a lesser extent, increased administrative fees and other revenue in our Other segment and higher premiums in our Commercial & Specialty Business segment.
Net income for the three months ended September
30, 2019 was $1,183, an increase of $223, or 23.2%, from the three months ended September 30, 2018. The increase in net income for the three months ended September 30, 2019 compared to 2018 was driven by improved operating results in our Government Business and Commercial & Specialty Business segments. Net income for the nine months ended September 30, 2019 was $3,873, an increase of
$548, or 16.5%, from the nine months ended September 30, 2018. The increase in net income for the nine months ended September 30, 2019 compared to 2018 was due to improved operating results in our Commercial & Specialty Business segment and lower income tax expense.
Our diluted earnings per share, or EPS, was $4.55 for the three months ended September 30, 2019, which represented a 25.7%increase from EPS of $3.62 for the three months ended September 30, 2018. Our fully-diluted EPS was $14.83 for the
-43-
nine months ended September 30, 2019, which represented a 17.9%increase from fully-diluted EPS of $12.58 for the nine months
ended September 30, 2018. The increase in EPS for the three and nine months ended September 30, 2019 compared to 2018 resulted from the increase in net income in 2019, and to a lesser extent, the lower number of shares outstanding in 2019.
Operating cash flow for the nine months ended September 30, 2019 and 2018 was $4,734 and $3,364, respectively. This increase
was primarily due to the impact of membership increases in our Medicaid and Medicare businesses. These increases were partially offset by lower premium receipts as a result of the suspension of the HIP Fee for 2019.
-44-
Membership
The following table presents our medical membership by customer type, funding arrangement and reportable segment as of September 30, 2019 and 2018.
Also included below is other membership by product. The medical membership and other membership data presented are unaudited and in certain instances include estimates of the number of members represented by each contract at the end of the period.For a more detailed description of our medical membership, see the “Membership” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2018 Annual Report on Form 10-K.
September
30
(In thousands)
2019
2018 1
Change
% Change
Medical
Membership
Customer Type
Local
Group
15,659
15,688
(29
)
(0.2
)%
Individual
711
692
19
2.7
%
National:
National
Accounts
7,666
7,610
56
0.7
%
BlueCard®
5,967
5,794
173
3.0
%
Total
National
13,633
13,404
229
1.7
%
Medicare:
Medicare
Advantage
1,203
992
211
21.3
%
Medicare Supplement
893
837
56
6.7
%
Total
Medicare
2,096
1,829
267
14.6
%
Medicaid
7,293
6,731
562
8.3
%
Federal
Health Products & Services
1,592
1,557
35
2.2
%
Total Medical Membership by Customer Type
40,984
39,901
1,083
2.7
%
Funding
Arrangement
Self-Funded
25,368
25,253
115
0.5
%
Fully-Insured
15,616
14,648
968
6.6
%
Total
Medical Membership by Funding Arrangement
40,984
39,901
1,083
2.7
%
Reportable Segment
Commercial
& Specialty Business
30,003
29,784
219
0.7
%
Government Business
10,981
10,117
864
8.5
%
Total
Medical Membership by Reportable Segment
40,984
39,901
1,083
2.7
%
Other Membership
Life
and Disability Members
4,970
4,701
269
5.7
%
Dental Members
5,942
5,804
138
2.4
%
Dental
Administration Members
5,526
5,367
159
3.0
%
Vision Members
7,232
6,906
326
4.7
%
Medicare
Part D Standalone Members
285
312
(27
)
(8.7
)%
1
During
the fourth quarter of 2018, we made a number of changes to our membership reporting to better align our reported membership to the appropriate type, funding arrangement and segment. Accordingly, certain types of membership have been reclassified to conform to the current year presentation.
-45-
Medical Membership
Total medical membership increased across our reportable business segments and the increase was driven primarily by growth in our fully-insured businesses. Fully-insured membership increased primarily due to growth in our Medicaid, Medicare and National Accounts businesses. Self-funded medical membership increased primarily due to
higher activity from BlueCard® membership, partially offset by the decrease in our Large Group self-funded membership, which declined as a result of competitive pressures. Medicaid membership increased primarily due to new businesses and expansions, partially offset by the membership decrease resulting from the loss of a contract. Medicare membership increased primarily due to higher sales during open enrollment exceeding lapses. BlueCard® membership increased due to higher membership activity at other Blue Cross and Blue Shield Association, or BCBSA, plans whose members reside in or travel to our licensed areas. National Accounts membership increased primarily
due to new sales.
Other Membership
Our other membership can be impacted by changes in our medical membership, as our medical members often purchase our other products that are ancillary to our health business. We have experienced growth in our life and disability and dental memberships primarily due to higher sales in our Large Group business. Dental administration membership increased primarily due to in-group changes. Vision membership increased due to higher sales in our Medicare and Large Group businesses.
-46-
Consolidated
Results of Operations
Our consolidated summarized results of operations and other financial information for the three and nine months ended September 30, 2019 and 2018 are as follows:
Three
Months Ended September 30
Nine Months Ended September 30
Change
Three Months Ended September 30
Nine Months Ended September 30
2019
vs. 2018
2019 vs. 2018
2019
2018
2019
2018
$
%
$
%
Total operating revenue
$
26,444
$
22,980
$
76,009
$
68,037
$
3,464
15.1
%
$
7,972
11.7
%
Net
investment income
242
250
737
708
(8
)
(3.2
)%
29
4.1
%
Net
realized gains on financial instruments
1
27
90
5
(26
)
(96.3
)%
85
1,700.0
%
Other-than-temporary
impairment losses recognized in income
(13
)
(6
)
(30
)
(18
)
(7
)
116.7
%
(12
)
66.7
%
Total
revenues
26,674
23,251
76,806
68,732
3,423
14.7
%
8,074
11.7
%
Benefit
expense
20,753
18,185
60,403
52,959
2,568
14.1
%
7,444
14.1
%
Cost
of products sold
745
—
843
—
745
NM
843
NM
Selling,
general and administrative expense
3,418
3,546
9,862
10,402
(128
)
(3.6
)%
(540
)
(5.2
)%
Other
expense1
269
278
811
846
(9
)
(3.2
)%
(35
)
(4.1
)%
Total
expenses
25,185
22,009
71,919
64,207
3,176
14.4
%
7,712
12.0
%
Income
before income tax expense
1,489
1,242
4,887
4,525
247
19.9
%
362
8.0
%
Income
tax expense
306
282
1,014
1,200
24
8.5
%
(186
)
(15.5
)%
Net
income
$
1,183
$
960
$
3,873
$
3,325
$
223
23.2
%
$
548
16.5
%
Average
diluted shares outstanding
260.0
265.4
261.1
264.3
(5.4
)
(2.0
)%
(3.2
)
(1.2
)%
Diluted
net income per share
$
4.55
$
3.62
$
14.83
$
12.58
$
0.93
25.7
%
$
2.25
17.9
%
Effective
tax rate
20.6
%
22.7
%
20.7
%
26.5
%
(210)bp3
(580)bp3
Benefit
expense ratio2
87.2
%
84.8
%
86.1
%
83.3
%
240bp3
280bp3
Selling,
general and administrative expense ratio4
12.9
%
15.4
%
13.0
%
15.3
%
(250)bp3
(230)bp3
Income
before income tax expense as a percentage of total revenues
5.6
%
5.3
%
6.4
%
6.6
%
30bp3
(20)bp3
Net
income as a percentage of total revenues
4.4
%
4.1
%
5.0
%
4.8
%
30bp3
20bp3
Certain
of the following definitions are also applicable to all other results of operations tables in this discussion:
NM
Not meaningful.
1
Includes interest expense, amortization of other intangible assets and (gain) loss on extinguishment of debt.
2
Benefit expense ratio represents benefit expense as a percentage of premium
revenue. Premiums for the three months ended September 30, 2019 and 2018 were $23,793 and $21,451, respectively. Premiums for the nine months ended September 30, 2019 and 2018 were $70,137 and $63,602, respectively. Premiums are included in total operating revenue presented above.
3
bp
= basis point; one hundred basis points = 1%.
4
Selling, general and administrative expense ratio represents selling, general and administrative expense as a percentage of total operating revenue.
The increase in total operating revenue was primarily due to higher premiums and increased administrative fees and other revenue. The higher
premiums were due to membership growth primarily in our Government Business segment. The increase was further attributable to rate increases across our businesses designed to cover overall cost trends. These increases in premiums were partially offset by the impact of the HIP Fee suspension for 2019. The increase in administrative fees and other revenue was primarily driven by IngenioRx, which began its operations during the second quarter of 2019.
-47-
Benefit expense increased primarily due to membership growth across our reportable business segments.
Our benefit expense
ratio increased largely due to the loss of revenue associated with the HIP Fee suspension for 2019.
Cost of products sold reflects the cost of pharmaceuticals dispensed by IngenioRx for our self-funded customers. IngenioRx began operations during the second quarter of 2019, so there was no cost of products sold recognized in 2018.
Our selling, general and administrative expense decreased primarily due to the suspension of the HIP Fee for 2019. This decrease was partially offset by a net increase in spend to support growth in our businesses.
Our selling, general and administrative expense ratio decreased due to the growth in operating revenue and the suspension of the HIP Fee for
2019.
Our income tax expense increased primarily due to the 2018 remeasurement of deferred tax assets and liabilities against the prior year provisional estimates pursuant to the Tax Cuts and Jobs Act. This increase was partially offset by the suspension of the non-tax deductible HIP Fee for 2019. Our effective tax rate decreased primarily due to the suspension of the non-tax deductible HIP Fee for 2019.
Our net income as a percentage of total revenue increased in 2019 as compared to 2018 as a result of all factors discussed above.
The increase in total operating revenue was primarily from higher premiums, and, to a lesser extent, increased administrative fees and other revenue. The higher premiums were largely due to new Medicaid businesses and expansions and membership growth in our Medicare business. The increase in premiums was further attributable to rate increases across our businesses designed to cover overall cost trends. These increases were partially offset by the impact of the HIP Fee suspension for 2019. The increase in administrative fees and other revenue was primarily driven by Ingenio Rx, which began its operations during the second quarter of 2019.
Net realized gains on financial instruments increased
due to an increase in net realized gains on sales of equity securities.
Benefit expense increased due to membership growth across our businesses and higher medical cost experience in our Medicaid business.
Our benefit expense ratio increased largely due to the loss of revenue associated with the HIP Fee suspension for 2019. Our benefit expense ratio was further impacted by higher medical cost experience in our Medicaid business.
Cost of products sold reflects the cost of pharmaceuticals dispensed by IngenioRx for our self-funded customers. IngenioRx began operations during the second quarter of 2019, so there was no cost of products sold recognized in 2018.
Our selling, general and
administrative expense decreased primarily due to the suspension of the HIP Fee for 2019. This decrease was partially offset by a net increase in spend to support growth in our businesses.
Our selling, general and administrative expense ratio decreased due to the growth in operating revenue and the suspension of the HIP Fee for 2019.
Our income tax expense and effective tax rate decreased primarily due to the suspension of the non-tax deductible HIP Fee for 2019.
Our net income as a percentage of total revenue increased in 2019 as compared to 2018 as a result of all factors discussed above.
Reportable
Segments Results of Operations
Our results of operations discussed throughout this MD&A are determined in accordance with U.S. generally accepted accounting principles, or GAAP. We also calculate operating gain and operating margin, non-GAAP measures, to further aid investors in understanding and analyzing our core operating results and comparing them among periods. We define operating
-48-
revenue as premium income and administrative fees and other revenue. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense. It does not include net investment income, net realized
gains on financial instruments, other than temporary impairment losses recognized in income, interest expense, amortization of other intangible assets, (gain) loss on extinguishment of debt or income taxes, as these items are managed in our corporate shared service environment and are not the responsibility of operating segment management. Operating margin is calculated as operating gain divided by operating revenue. We use these measures as a basis for evaluating segment performance, allocating resources, forecasting future operating periods and setting incentive compensation targets. This information is not intended to be considered in isolation or as a substitute for income before income tax expense, net income or EPS, prepared in accordance with GAAP, and may not be comparable to similarly titled measures reported by other companies. For a reconciliation of reportable segments’ operating revenue to the amounts of total revenue included in the consolidated statements
of income and a reconciliation of reportable segments’ operating gain to income before income tax expense, see Note 15, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Prior to the second quarter of 2019, our Other segment included certain eliminations and corporate expenses not allocated to either of our other reportable segments. Beginning in the second quarter of 2019, our Other segment also includes IngenioRx, our PBM, which began its operations during the second quarter of 2019. In addition, during the second quarter, we reclassified our Diversified Business Group, or DBG, our integrated health services business, from our Government Business segment to the Other segment to reflect changes in how our segments are being managed. Amounts for 2018 have been reclassified to conform to the current year presentation for comparability. Based
on the Financial Accounting Standards Board guidance, as of September 30, 2019, IngenioRx and DBG do not collectively meet the quantitative thresholds for an operating segment.
Affiliated revenues represent revenues or cost for services provided by IngenioRx and DBG to our subsidiaries, are recorded at cost or management’s estimate of fair market value, and are eliminated in consolidation.
For our segment reporting, operating gains (losses) generated from IngenioRx and DBG affiliated activity have been included in our Commercial & Specialty Business and Government Business based upon their utilization of services from IngenioRx and DBG.
-49-
The
following table presents a summary of the reportable segment financial information for the three and nine months ended September 30, 2019 and 2018:
Three
Months Ended September 30
Nine Months Ended September 30
Change
Three Months Ended September 30
Nine Months Ended September 30
2019
vs. 2018
2019 vs. 2018
2019
2018 1
2019
2018 1
$
%
$
%
Operating Revenue
Commercial
& Specialty Business
$
9,284
$
8,933
$
28,093
$
26,939
$
351
3.9
%
$
1,154
4.3
%
Government
Business
15,955
13,979
46,419
40,951
1,976
14.1
%
5,468
13.4
%
Other
2,508
398
3,850
1,108
2,110
530.2
%
2,742
247.5
%
Eliminations
(1,303
)
(330
)
(2,353
)
(961
)
(973
)
NM
(1,392
)
NM
Total
operating revenue
$
26,444
$
22,980
$
76,009
$
68,037
$
3,464
15.1
%
$
7,972
11.7
%
Operating
Gain (Loss)
Commercial
& Specialty Business
$
930
$
834
$
3,511
$
3,284
$
96
11.5
%
$
227
6.9
%
Government
Business
616
456
1,471
1,477
160
35.1
%
(6
)
(0.4
)%
Other
(18
)
(41
)
(81
)
(85
)
23
(56.1
)%
4
(4.7
)%
Operating
Margin
Commercial
& Specialty Business
10.0
%
9.3
%
12.5
%
12.2
%
70
bp
30
bp
Government
Business
3.9
%
3.3
%
3.2
%
3.6
%
60
bp
(40
)bp
1
During
the second quarter of 2019, we reclassified DBG from our Government Business segment to our Other segment to reflect changes in how our segments are being managed. Accordingly, certain amounts for the three and nine months ended September 30, 2018 have been reclassified to conform to the current year presentation for comparability.
Operating
revenue increased primarily due to higher premium revenue resulting from rate increases in our Local Group business designed to cover overall cost trends and due to membership increases in our fully-insured National Accounts and Individual ACA businesses. These increases were partially offset by the impact of the HIP Fee suspension for 2019.
The increase in operating gain was primarily driven by greater penetration of value-added services, including our pharmacy and integrated health offerings. This increase was partially offset by unfavorable reserve development.
Government Business
Operating revenue increased primarily due to higher premium revenue as a result of new Medicaid businesses and expansions, including specialized service populations,
and membership growth in our Medicare business. The increase in premium revenue was further attributable to rate increases designed to cover overall cost trends in our Medicaid and Medicare businesses, and increased reimbursed benefit utilization in our Federal Health Products and Services, or FHPS, business. These increases were partially offset by the impact of the HIP Fee suspension for 2019.
Operating gain increased as a result of improved medical cost performance in our Medicaid business. The increase was partially offset by the impact of the HIP Fee suspension for 2019.
-50-
Other
Operating
revenue increased due to higher administrative fees and other revenue from IngenioRx and DBG. The increase was primarily driven by growth in our pharmacy services provided by IngenioRx, which commenced operations during the second quarter of 2019 and continued migrating pharmacy services from Express Scripts during the third quarter of 2019.
Operating loss increased primarily as a result of changes in unallocated corporate expenses.
Operating revenue increased
primarily due to higher premium revenue, and to a lesser extent, increased administrative fees and other revenue. Premium revenue was higher as a result of rate increases in our Local Group business designed to cover overall cost trends and membership increases in our fully-insured National Accounts and Individual ACA businesses. These increases in premium revenue were partially offset by the impact of the HIP Fee suspension for 2019. The increase in administrative fees and other revenues was due to higher penetration of value-added services for self-funded members in our Large Group and National Accounts businesses.
The increase in operating gain was primarily driven by greater penetration of value-added services, including our pharmacy and integrated health offerings. This increase was partially offset by the impact of the HIP Fee suspension for 2019 and higher favorable adjustments recognized in 2018 related to estimates
for the ACA risk adjustment premium stabilization program.
Government Business
Operating revenue increased primarily due to higher premium revenue as a result of new Medicaid businesses and expansions, including specialized service populations, and membership growth in our Medicare business. The increase in premium revenue was further attributable to rate increases designed to cover overall cost trends in our Medicare and Medicaid businesses as well as increased reimbursed benefit utilization in our FHPS business. These increases were partially offset by the impact of the HIP Fee suspension for 2019.
Operating gain decreased due to the impact of the HIP Fee suspension for 2019 and continued elevated medical cost experience in our Medicaid business
in certain states. These decreases were mostly offset by the membership growth in our Medicaid and Medicare businesses.
Other
Operating revenue increased due to higher administrative fees and other revenue from IngenioRx and DBG. The increase was primarily driven by growth in our pharmacy services provided by IngenioRx, which commenced operations during the second quarter of 2019 and continued migrating pharmacy services from Express Scripts during the third quarter of 2019.
Operating loss decreased primarily as a result of changes in unallocated corporate expenses.
Critical Accounting Policies and Estimates
We prepare our consolidated
financial statements in conformity with GAAP. Application of GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes and within this MD&A. We consider our most important accounting policies that require significant estimates and management judgment to be those policies with respect to liabilities for medical claims payable, income taxes, goodwill and other intangible assets, investments and retirement benefits. Our accounting policies related to these items are discussed in our 2018 Annual Report on Form 10-K in Note 2, “Basis of Presentation and Significant Accounting Policies,” to our audited consolidated financial statements as of and for the year ended December 31, 2018, as well as in the “Critical Accounting Policies
and Estimates” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” As of September 30, 2019, our critical accounting policies and estimates have not changed from those described in our 2018 Annual Report on Form 10-K.
-51-
Medical Claims Payable
The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims payable. Our accounting policies related to medical claims payable are discussed in the
references cited above. As of September 30, 2019, our critical accounting policies and estimates related to medical claims payable have not changed from those described in our 2018 Annual Report on Form 10-K. For a reconciliation of the beginning and ending balance for medical claims payable for the nine months endedSeptember 30, 2019 and 2018, see Note 9, “Medical Claims Payable,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
The following table provides a summary of the two key assumptions having
the most significant impact on our incurred but not paid liability estimates for the nine months ended September 30, 2019 and 2018, which are the trend and completion factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations.
Favorable Developments by Changes in Key
Assumptions
Nine Months Ended September 30
2019
2018
Assumed
trend factors
$
311
$
477
Assumed completion factors
126
381
Total
$
437
$
858
The
favorable development recognized in the nine months ended September 30, 2019 and 2018 resulted from trend factors in late 2018 and late 2017, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter parts of 2018 and 2017 developing faster than expected also contributed to the favorability.
The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 85.5% and 86.6%
for the nine months ended September 30, 2019 and 2018, respectively. This ratio serves as an indicator of claims processing speed whereby claims were processed slightly faster during the nine months ended September 30, 2018.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net medical claims payable less prior year redundancies in the current period in order to demonstrate the development of the prior year reserves. For the nine months ended September 30, 2019, this metric was 6.4%,
largely driven by favorable trend factor development at the end of 2018. For the nine months ended September 30, 2018, this metric was 12.5%, largely driven by favorable trend factor development at the end of 2017 as well as favorable completion factor development from 2017.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net incurred medical claims to indicate the percentage of redundancy included in the preceding year calculation of current year net incurred medical claims. We believe this calculation supports the reasonableness of our prior year estimate of incurred medical claims and the consistency in our methodology. For the nine
months ended September 30, 2019, this metric was 0.6%, which was calculated using the redundancy of $437. For the nine months ended September 30, 2018, the comparable metric was 1.2%, which was calculated using the redundancy of $858. We believe these metrics demonstrate a generally consistent level of reserve conservatism.
New Accounting Pronouncements
For information regarding new accounting pronouncements that were adopted and new accounting pronouncements that were issued during the nine months ended September
30, 2019, see the “Recently Adopted Accounting Guidance” and “Recent Accounting Guidance Not Yet Adopted” sections of Note 2, “Basis of Presentation and Significant Accounting Policies” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
-52-
Liquidity and Capital Resources
Sources and Uses of Capital
Our cash receipts result primarily
from premiums, administrative fees and other revenue, investment income, proceeds from the sale or maturity of our investment securities, proceeds from borrowings, and proceeds from the issuance of common stock under our employee stock plans. Cash disbursements result mainly from claims payments, administrative expenses, taxes, purchases of investment securities, interest expense, payments on borrowings, acquisitions, capital expenditures, repurchases of our debt securities and common stock and the payment of cash dividends. Cash outflows fluctuate with the amount and timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on our liquidity.
For a more detailed overview of our liquidity and capital resources management, see the “Introduction” section included in the “Liquidity and Capital Resources” section
of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2018 Annual Report on Form 10-K.
For additional information regarding our sources and uses of capital during the three and nine months ended September 30, 2019, see Note 5, “Derivative Financial Instruments,” Note 10, “Debt,” and Note 12, “Capital Stock - Use of Capital - Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Liquidity
A summary of our major sources and uses of cash
and cash equivalents for the nine months ended September 30, 2019 and 2018 is as follows:
Nine Months Ended September 30
2019 vs. 2018
2019
2018
Change
Sources
of Cash:
Net cash provided by operating activities
$
4,734
$
3,364
$
1,370
Issuance
of common stock under Equity Units stock purchase contracts
—
1,250
(1,250
)
Issuances of commercial paper and short- and long-term debt, net of repayments
918
—
918
Proceeds
from sales, maturities, calls and redemptions of investments, net of purchases
—
857
(857
)
Proceeds from issuance of common stock under employee stock plans
137
133
4
Changes
in bank overdrafts
250
97
153
Other sources of cash, net
139
326
(187
)
Total
sources of cash
6,178
6,027
151
Uses of Cash:
Purchases
of investments, net of proceeds from sales, maturities, calls and redemptions
Repayments
of commercial paper and short- and long-term debt, net of issuances
—
(617
)
617
Cash dividends
(616
)
(583
)
(33
)
Other
uses of cash, net
(288
)
(363
)
75
Total uses of cash
(5,921
)
(5,375
)
(546
)
Effect
of foreign exchange rates on cash and cash equivalents
(1
)
(1
)
—
Net increase in cash and cash equivalents
$
256
$
651
$
(395
)
-53-
The
increase in cash provided by operating activities was primarily due to the impact of membership increases in our Medicaid and Medicare businesses. These increases were partially offset by lower premium receipts as a result of the suspension of the HIP Fee for 2019.
Other significant changes in sources or uses of cash year-over-year included an increase in net purchases of investments in 2019 compared to net proceeds from sales, maturities, calls and redemptions of investments in 2018, an increase in net proceeds from the issuance of commercial paper and short- and long-term debt in 2019 compared to net repayments in 2018, a decrease in cash received from the issuance of common stock under Equity Units stock purchase contracts and a decrease in cash paid for acquisitions.
Financial
Condition
We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and investments in fixed maturity and equity securities of $26,997 at September 30, 2019. Since December 31, 2018, total cash, cash equivalents and investments in fixed maturity and equity securities increased by $4,358, primarily due to cash generated from operations.
Many of our subsidiaries are subject to various government regulations that restrict
the timing and amount of dividends and other distributions that may be paid to their respective parent companies. Certain accounting practices prescribed by insurance regulatory authorities, or statutory accounting practices, differ from GAAP. Changes that occur in statutory accounting practices, if any, could impact our subsidiaries’ future dividend capacity. In addition, we have agreed to certain undertakings to regulatory authorities, including requirements to maintain certain capital levels in certain of our subsidiaries.
At September 30, 2019, we held $2,998 of cash, cash equivalents and investments
at the parent company, which are available for general corporate use, including investment in our businesses, acquisitions, potential future common stock repurchases and dividends to shareholders, repurchases of debt securities and debt and interest payments.
Debt
Periodically, we access capital markets and issue debt, or Notes, for long-term borrowing purposes, for example, to refinance debt, to finance acquisitions or for share repurchases. Certain of these Notes may have a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. For more information on our debt, including redemptions and issuances, see Note 10, “Debt” of the Notes to Consolidated Financial Statements included
in Part I, Item 1 of this Form 10-Q.
We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, from the amounts presented on our consolidated balance sheets included in Part I, Item 1 of this Form 10-Q. Our debt-to-capital ratio is calculated as total debt divided by total debt plus total shareholders’ equity. Total debt is the sum of short-term borrowings, current portion of long-term debt, long-term debt, less current portion, and beginning January 1, 2019, lease liabilities. We believe our debt-to-capital ratio assists investors and rating agencies in measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a maximum debt-to-capital ratio that we cannot and did not exceed. Our debt-to-capital ratio may not be comparable to similarly titled measures reported by other companies. Our consolidated debt-to-capital
ratio was 40.0% and 40.2% as of September 30, 2019 and December 31, 2018, respectively.
Our senior debt is rated “A” by S&P Global Ratings, “BBB” by Fitch Ratings, Inc., “Baa2” by Moody’s Investor Service, Inc. and “bbb+” by AM Best Company, Inc. We intend to maintain our senior debt investment grade ratings. If our credit ratings are downgraded, our business, liquidity, financial condition and results of operations could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing costs.
Future Sources and Uses of Liquidity
We
have a shelf registration statement on file with the U.S. Securities and Exchange Commission to register an unlimited amount of any combination of debt or equity securities in one or more offerings. Specific information regarding terms and securities being offered will be provided at the time of an offering. Proceeds from future offerings are expected to be used for
-54-
general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of credit to our subsidiaries and the financing of possible acquisitions or business expansions.
We
regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
For additional information regarding our sources and uses of capital at September 30, 2019, see Note 4, “Investments,” Note 5, “Derivative Financial Instruments,” Note 10, “Debt” and Note 12, “Capital Stock - Use of Capital - Dividends and Stock Repurchase Program” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Form 10-Q.
Risk-Based Capital
Our regulated subsidiaries’ states of domicile have statutory risk-based capital, or RBC, requirements for health and other insurance companies and health maintenance organizations largely based on the National Association of Insurance Commissioners, or NAIC, RBC Model Act. These RBC requirements are intended to measure capital adequacy, taking into account the risk characteristics of an insurer’s investments and products. The NAIC sets forth the formula for calculating the RBC requirements, which are designed to take into account asset risks, insurance risks, interest rate risks and other relevant risks with respect to an individual insurance company’s business. In general, under the RBC Model Act, an insurance company
must submit a report of its RBC level to the state insurance department or insurance commissioner, as appropriate, at the end of each calendar year. Our regulated subsidiaries’ respective RBC levels as of December 31, 2018, which was the most recent date for which reporting was required, were in excess of all mandatory RBC requirements. In addition to exceeding the RBC requirements, we are in compliance with the liquidity and capital requirements for a licensee of the BCBSA and with the tangible net equity requirements applicable to certain of our California subsidiaries.
For additional information, see Note 21, “Statutory Information,” in our
audited consolidated financial statements as of and for the year ended December 31, 2018 included in our 2018 Annual Report on Form 10-K.
Contractual Obligations and Commitments
We believe that funds from future operating cash flows, cash and investments and funds available under our 5-year and 364-day senior revolving credit facilities and/or from public or private financing sources will be sufficient for future operations and commitments, and for capital acquisitions and other strategic transactions.
There have been no material changes to our Contractual Obligations and Commitments disclosure in our 2018 Annual Report on Form 10-K other than debt issuances.
For additional information regarding our estimated contractual obligations and commitments, see Note 5, “Derivative Financial Instruments,” Note 10, “Debt,” and the “Other Contingencies” and “Contractual Obligations and Commitments” sections of Note 11, “Commitments and Contingencies,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
-55-
FORWARD-LOOKING
STATEMENTS
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,”“feel,”“believe,”“will,”“may,”“should,”“anticipate,”“intend,”“estimate,”“project,”“forecast,”“plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult
to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent otherwise required by federal securities laws, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof. These risks and uncertainties include, but are not limited to: the impact of federal and state regulation, including ongoing changes in the Patient Protection and Affordable Care Act and the Health
Care and Education Reconciliation Act of 2010, as amended, or collectively, the ACA, and the ultimate outcome of legal challenges to the ACA; trends in healthcare costs and utilization rates; our ability to contract with providers on cost-effective and competitive terms; our ability to secure sufficient premium rates, including regulatory approval for and implementation of such rates; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; reduced enrollment; unauthorized disclosure of member or employee sensitive or confidential information, including the impact and outcome of any investigations, inquiries, claims and litigation related thereto; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our
ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services, or CMS, Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; the ultimate outcome of litigation between Cigna Corporation, or Cigna, and us related to the merger agreement between the parties, including our claim for damages against Cigna, Cigna’s claim for payment of a termination fee and other damages against us, and the potential for such litigation to cause us to incur substantial costs, materially distract management and negatively impact our reputation and financial condition; non-compliance by any party with the pharmacy benefit management services agreements between us and each of Express Scripts, Inc., or Express Scripts, and CaremarkPCS Health, L.L.C., or CVS
Health, as well as any agreements governing the transition of pharmacy benefit management services provided to us from Express Scripts to CVS Health, which could result in financial penalties, our inability to meet customer demands, and sanctions imposed by governmental entities, including CMS; medical malpractice or professional liability claims or other risks related to healthcare services and pharmacy benefit management services provided by our subsidiaries; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our
substantial amount of outstanding indebtedness; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; failure to effectively maintain and modernize our information systems; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; large scale medical emergencies, such as future public health epidemics and catastrophes; general risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; changes in U.S. tax laws; intense competition to attract and retain employees; and various laws and provisions in our governing documents that may prevent
or discourage takeovers and business combinations.
-56-
ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For a discussion of our market risks, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” included in our 2018 Annual Report on Form 10-K. There have been no material changes to any of these risks since December 31,
2018.
ITEM 4.
CONTROLS AND PROCEDURES
We carried out an evaluation as of September 30, 2019, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Based upon that evaluation, the Chief Executive
Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to us (including our consolidated subsidiaries) required to be disclosed in our reports under the Exchange Act. In addition, based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.
During the three months ended September 30, 2019,
we implemented certain additional internal controls associated with our new IngenioRx pharmacy business. Other than these new controls, there have been no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1.
LEGAL
PROCEEDINGS
For information regarding legal proceedings at September 30, 2019, see the “Litigation and Regulatory Proceedings,” and “Other Contingencies” sections of Note 11, “Commitments and Contingencies” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
ITEM 1A.
RISK FACTORS
There
have been no material changes to the risk factors disclosed in our 2018 Annual Report on Form 10-K.
-57-
ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities
The following table presents information related to our repurchases of common stock for the periods indicated:
Total
number of shares purchased includes 7,452 shares delivered to or withheld by us in connection with employee payroll tax withholding upon exercise or vesting of stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the consolidated statements of shareholders’ equity are shown net of these shares purchased.
2
Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of Directors, which the Board of Directors evaluates periodically. During the three months ended September 30, 2019, we repurchased 2,414,739
shares at a cost of $644 under the program, including the cost of options to purchase shares. The Board of Directors has authorized our common stock repurchase program since 2003. The Board of Director’s most recent authorized increase to the program was $5,000 on December 7, 2017. Between October 1, 2019 and October 16, 2019, we repurchased 434,700 shares at a cost of $104 bringing our current availability to $3,994 at October 16, 2019. No duration has been placed on our common stock repurchase program,
and we reserve the right to discontinue the program at any time.
Upon the request of the U.S. Securities and Exchange Commission, the Company will furnish copies of any other instruments defining the rights of holders of long-term debt of the Company or its subsidiaries.
The following material from Anthem, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, formatted in Inline XBRL (Inline Extensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii)
the Consolidated Statements of Income; (iii) the Consolidated Statements of Comprehensive Income; (iv) the Consolidated Statements of Cash Flows; (v) the Consolidated Statements of Shareholders’ Equity; and (vi) Notes to Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104
Cover Page Interactive
Data File formatted in Inline XBRL and contained in Exhibit 101.
*
Indicates management contracts
or compensatory plans or arrangements.
-59-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
